<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Immunol Res</journal-id><journal-id journal-id-type="iso-abbrev">J Immunol Res</journal-id><journal-id journal-id-type="pmc-domain-id">2403</journal-id><journal-id journal-id-type="pmc-domain">jimmres</journal-id><journal-id journal-id-type="publisher-id">jir</journal-id><journal-title-group><journal-title>Journal of Immunology Research</journal-title></journal-title-group><issn pub-type="ppub">2314-8861</issn><issn pub-type="epub">2314-7156</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11019575</article-id><article-id pub-id-type="pmcid-ver">PMC11019575.1</article-id><article-id pub-id-type="pmcaid">11019575</article-id><article-id pub-id-type="pmcaiid">11019575</article-id><article-id pub-id-type="pmid">38628675</article-id><article-id pub-id-type="doi">10.1155/2024/2147912</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>The Question of HIV Vaccine: Why Is a Solution Not Yet Available?</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Libera</surname><given-names initials="M">Martina</given-names></name><xref rid="I1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="I2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Caputo</surname><given-names initials="V">Valeria</given-names></name><xref rid="I1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="I2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2622-9631</contrib-id><name name-style="western"><surname>Laterza</surname><given-names initials="G">Giulia</given-names></name><xref rid="I1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="I3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Moudoud</surname><given-names initials="L">Louiza</given-names></name><xref rid="I1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="I2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7680-6068</contrib-id><name name-style="western"><surname>Soggiu</surname><given-names initials="A">Alessio</given-names></name><xref rid="I1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="I4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9364-095X</contrib-id><name name-style="western"><surname>Bonizzi</surname><given-names initials="L">Luigi</given-names></name><xref rid="I1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7853-3224</contrib-id><name name-style="western"><surname>Diotti</surname><given-names initials="RA">Roberta A.</given-names></name><email>diotti.robertaantonia@hsr.it</email><xref rid="I1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="I2" ref-type="aff">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="I1">
<sup>1</sup>One Health Unit, Department of Biomedical, Surgical and Dental Sciences, School of Medicine, University of Milan, Via Pascal 36, 20133 Milan, Italy</aff><aff id="I2">
<sup>2</sup>Pomona Ricerca S.r.l, Via Assarotti 7, 10122 Turin, Italy</aff><aff id="I3">
<sup>3</sup>Department of Clinical and Community Sciences, School of Medicine, University of Milan, Via Celoria 22, 20133 Milan, Italy</aff><aff id="I4">
<sup>4</sup>SC Maxillo-Facial Surgery and Dentistry, Fondazione IRCCS C&#224; Granda Ospedale Maggiore Policlinico, Via Francesco Sforza 35, 20133 Milan, Italy</aff><author-notes><fn fn-type="other"><p>Academic Editor: Shengjun Wang</p></fn></author-notes><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>8</day><month>4</month><year>2024</year></pub-date><volume>2024</volume><issue-id pub-id-type="pmc-issue-id">453123</issue-id><elocation-id>2147912</elocation-id><history><date date-type="received"><day>19</day><month>9</month><year>2023</year></date><date date-type="rev-recd"><day>4</day><month>12</month><year>2023</year></date><date date-type="accepted"><day>24</day><month>2</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>08</day><month>04</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>16</day><month>04</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-04-14 16:25:25.190"><day>14</day><month>04</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2024 Martina Libera et al.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="JIR2024-2147912.pdf"/><abstract><p>Ever since its discovery, human immunodeficiency virus type 1 (HIV-1) infection has remained a significant public health concern. The number of HIV-1 seropositive individuals currently stands at 40.1 million, yet definitive treatment for the virus is still unavailable on the market. Vaccination has proven to be a potent tool in combating infectious diseases, as evidenced by its success against other pathogens. However, despite ongoing efforts and research, the unique viral characteristics have prevented the development of an effective anti-HIV-1 vaccine. In this review, we aim to provide an historical overview of the various approaches attempted to create an effective anti-HIV-1 vaccine. Our objective is to explore the reasons why specific methods have failed to induce a protective immune response and to analyze the different modalities of immunogen presentation. This trial is registered with <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT05414786" ext-link-type="uri">NCT05414786</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT05471076" ext-link-type="uri">NCT05471076</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04224701" ext-link-type="uri">NCT04224701</ext-link>, and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01937455" ext-link-type="uri">NCT01937455</ext-link>.</p></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>The HIV-1 pandemic has persisted as one of the world's greatest health threats since the early 1980s, and after almost 40 years of intensive research, neither a resolutive cure nor a vaccine have been developed. Despite the important role that pre-exposure prophylaxis (PrEP) and antiretroviral therapy (ART) play, it should not distract the scientific community from developing a vaccine for HIV-1 eradication [<xref rid="B1" ref-type="bibr">1</xref>]. Developing countries have the highest incidence of infection, and about nine out of 10 sick people cannot afford these life-lasting medications [<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>]. In addition, the urgent progression toward a HIV-1 vaccine is also due to some important pharmacological limitations such as the occurrence of drug-resistant viral variants, adverse effects, and interactions with different medications [<xref rid="B3" ref-type="bibr">3</xref>]. Since 1796, the traditional workflow of isolating and inactivating or attenuating the virus, followed by injection, was found to be extremely effective and, in the past, it was applied to treat HIV-1 infection with inconclusive results [<xref rid="B4" ref-type="bibr">4</xref>]. Due to this failure, many other immunogens and different vaccines have been proposed and studied, but up today an effective anti-HIV-1 vaccine is not yet available. However, it is important to consider that the advancement of vaccine, but also treatment, development is hindered by the high genetic variability of HIV-1. This peculiar characteristic of HIV-1, manifested as viral quasispecies, enables the virus to evade both immune responses and treatment pressures [<xref rid="B5" ref-type="bibr">5</xref>]. This high diversity is influenced by several factors, with the most significant being the high mutation rate [<xref rid="B6" ref-type="bibr">6</xref>] and retroviral recombination [<xref rid="B7" ref-type="bibr">7</xref>]. The rate of error-prone nature of reverse transcriptase in HIV-1 is approximately 1.4&#8201;&#215;&#8201;10<sup>&#8722;5</sup> errors per base pair per replication cycle [<xref rid="B6" ref-type="bibr">6</xref>]. This translates to approximately 0.1 mutations synthesized per genome. Alongside, mutations can also be introduced by the influence of mutagenic factors within host cells, such as APOBEC3G [<xref rid="B8" ref-type="bibr">8</xref>]. Nevertheless, the adaptive flexibility of HIV-1 cannot be solely explained by mutations. In fact, retroviral recombination effectively drives the evolutionary mechanism [<xref rid="B7" ref-type="bibr">7</xref>].</p><p>The pivotal role of retroviral recombination mechanisms is to efficiently mix mutations within a quasispecies, thereby leading to the evolution of fitter forms that contribute to drug resistance [<xref rid="B9" ref-type="bibr">9</xref>].</p><p>This heterogeneity has been classified into groups, subtypes, and recombinant forms of the virus. There are currently four major groups of HIV-1 (M, O, N, and P), with group M being the most prevalent and diverse [<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B11" ref-type="bibr">11</xref>]. Within group M, there are nine subtypes and numerous circulating recombinant forms that result from recombination events between different subtypes [<xref rid="B12" ref-type="bibr">12</xref>]. The HIV-1 Env protein is certainly the protein most prone to genetic variations, as the immune response primarily targets this protein. Indeed, genetic diversity, which translate into antigenic variation, helps HIV-1 to evade immune detection. Typically, the onset of infection involves a relatively uniform viral population, characterized by less than 1% diversity in the <italic toggle="yes">env</italic> gene. As the asymptomatic phase progresses, this viral population undergoes diversification, peaking at up to 10% diversity in the <italic toggle="yes">env</italic> gene and increasing divergence. Subsequently, there is a stabilization or decrease in population diversity and divergence as the infection advances toward the AIDS phase [<xref rid="B13" ref-type="bibr">13</xref>]. Moreover, it was observed lengthening in the variable region V1V2 loop during the infection before declining in late-stage illness [<xref rid="B14" ref-type="bibr">14</xref>]. Notwithstanding, some other key factors contribute to the difficulty to develop effective vaccines. First off, the Env protein is composed of the outer envelope glycoprotein (gp120) and the transmembrane glycoprotein (gp41) and forms a trimer on the surface of the virus [<xref rid="B15" ref-type="bibr">15</xref>]. This heterotrimer is covered by approximately N-linked glycans, providing a shield that protects the underlying protein from immune recognition [<xref rid="B16" ref-type="bibr">16</xref>]. Moreover, HIV-1 displays around 14 trimers per virions, minimizing the immunogenicity of the particle [<xref rid="B17" ref-type="bibr">17</xref>]. Lastly, conformational flexibility of the Env protein during the attachment and fusion steps that help masking antibody epitopes [<xref rid="B18" ref-type="bibr">18</xref>].</p><p>In this scenario, it is simple to conclude that developing a vaccine capable of eliciting such a broad response is not easy.</p><p>In this review, we want to show the various immunogens studied, trying to explain the reasons why these strategies were unsuccessful according to the specificity of this virus. We will discuss from traditional to the most innovative vaccine strategies aimed at inducing a protective immune response.</p></sec><sec id="sec2"><title>2. Traditional Vaccinal Approaches</title><sec id="sec2.1"><title>2.1. Inactivated and Attenuated Vaccines</title><p>The traditional vaccine approaches based on the inactivation or attenuation of the pathogen had been successfully used since 1796, and they were initially attempted also for HIV-1. Although the killed whole-virus vaccine strategy has been neglected due to risks associated with partial viral inactivation and other technical challenges, one of the first adopted strategies was based on formaldehyde-inactivated HIV-1 in mice models. However, it was unsuccessful especially due to a cytotoxic effect of induced sera, which compromised the efficacy evaluation <italic toggle="yes">in vitro</italic> [<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B20" ref-type="bibr">20</xref>]. One of the first HIV-1 vaccines developed with a traditional approach was meant to be therapeutically administered to individuals who had already contracted HIV-1. Differently to prophylactic vaccines (useful to prevent the infection), the therapeutic approaches try to effectively eradicate the infection by modifying the immune response. The first therapeutic application of the inactivated virus, that was achieved through the chemical modification of gp120, was Remune, which phase III trial started already in 1997 [<xref rid="B21" ref-type="bibr">21</xref>]. Although initial results showed that combining this therapeutic vaccine with antiviral treatment led to an undetectable HIV-1 level, phase III trial was stopped because no difference between treated and untreated patients was observed [<xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B22" ref-type="bibr">22</xref>].</p><p>More recently, the safety and immunogenicity of a killed whole-HIV-1 vaccine (SAV001) were demonstrated in HIV-1 seropositive patients, underscoring the vital importance of preserving the natural structure of the envelope glycoproteins. This clinical trial has built upon a traditional killed whole-HIV-1 preparation, which underwent specific modification in the viral genome (<xref rid="tab1" ref-type="table">Table 1</xref>) to address safety concerns and achieve the necessary viral quantity. Notably, these modifications included the removal of the <italic toggle="yes">nef</italic> gene from the HIV-1 genome and the replacement of the envelope glycoprotein signal peptide gene. Following these genetic changes, the viral inactivation process involved chemical treatment and gamma irradiation, aimed at retaining the authentic viral conformation [<xref rid="B31" ref-type="bibr">31</xref>]. This clinical trial demonstrated that a vaccine based on killed whole HIV was able to induce a neutralizing immune response, which marks a significant initial step in the development of new vaccines [<xref rid="B32" ref-type="bibr">32</xref>]. However, no information about additional studies was provided.</p><p>Attenuated strategies were considered for the constitution of an effective vaccine, but evidences on a naturally occurring attenuated <italic toggle="yes">nef</italic>-deleted HIV-1 strain demonstrated immunologic damage in patients [<xref rid="B33" ref-type="bibr">33</xref>]. Moreover, there is the possibility of the integration of the proviral DNA of live attenuated virus into the host chromosomal DNA, establishing a persistent infection [<xref rid="B31" ref-type="bibr">31</xref>].</p></sec><sec id="sec2.2"><title>2.2. Protein-Based Vaccines</title><p>Other traditional approaches include protein-based vaccines, which focus on the main viral proteins targeted by humoral immune response. As will be further discussed, the role and the importance of the humoral response in protecting from infection was extensively demonstrated by <italic toggle="yes">in vivo</italic> and <italic toggle="yes">in vitro</italic> experimental studies [<xref rid="B34" ref-type="bibr">34</xref>]. For a hypervariable virus like HIV-1, a successful vaccine must induce antibodies (Abs) able to interfere with a broad spectrum of HIV-1 strains [<xref rid="B4" ref-type="bibr">4</xref>].</p><p>In the context of HIV-1, the principal targets of the immune system are the Env proteins (gp160, gp120, and gp41) [<xref rid="B35" ref-type="bibr">35</xref>&#8211;<xref rid="B37" ref-type="bibr">37</xref>]. The functional Env is a trimeric structure on HIV-1 virion surface, consisting of three noncovalently associated gp120 and gp41 proteins. The precursor polypeptide, gp160, undergoes cleavage to produce two crucial proteins: gp120, responsible for binding to cellular receptors, and gp41, that mediates fusion peptide between viral envelope and cellular membrane through its fusion peptide [<xref rid="B38" ref-type="bibr">38</xref>]. Despite many studies conducted in this direction, several clinical trials demonstrated the poor immunogenicity of monomeric gp120 (e.g., AIDSVAX). This could be linked to the production and structural arrangements of recombinant proteins, a crucial aspect in developing a potent vaccine, as demonstrated by other vaccine preparations. Moreover, based on Env conformation, HIV-1 can be divided into four tiers that mirror the sensitivity to antibody-mediated neutralization. Among these tiers, viruses belonging to tier 1A display increased sensitivity to antibodies-mediated neutralization, whereas those belonging to tier 3 exhibit reduced sensitivity [<xref rid="B39" ref-type="bibr">39</xref>].</p><p>As a result, numerous investigations were undertaken to obtain soluble trimers structures that mimic the native conformation of HIV-1 Env protein. One of the most successful soluble stabilized Env trimer is known as BG505 SOSIP.664, which was achieved by introducing specific modification into the native sequence. Specifically, BG505 SOSIP.664 is a truncated form of gp160 Env obtained introducing a stop codon at position 664 to remove the C-terminal, the transmembrane domain, and membrane proximal external region (MPER) domain, necessary to guarantee the high solubility of the protein [<xref rid="B40" ref-type="bibr">40</xref>]. To establish a connection between gp120 and gp41, an intermolecular disulfide bond (SOS) was introduced by A501C and T605C mutations [<xref rid="B41" ref-type="bibr">41</xref>] while the substitution I559P (isoleucine to proline, IP) stabilized the prefusion form of the protein [<xref rid="B42" ref-type="bibr">42</xref>]. Moreover, the final formulation of this protein includes a REKR cleavage site to enhance proteolytic cleavage for the generation of gp120 and gp41 components. The additional T332N mutation (threonine to asparagine) was introduced to restore the binding affinity for broadly neutralizing antibodies (bNAbs) targeting N332 glycan, a specific portion of gp120. Initially accomplished to Env sequence from BG505 strain, this modification was subsequently extended to Env proteins derived from other strains as well [<xref rid="B43" ref-type="bibr">43</xref>]. Maintaining key attributes of the native Env protein, this recombinant protein served as the subject of both structural and immunological studies [<xref rid="B42" ref-type="bibr">42</xref>]. Due to its specific interaction with neutralizing antibodies (NAbs) as opposed to non-neutralizing antibodies, BG505 SOSIP.664 was employed in immunizing animal models, leading to the isolation of monoclonal NAbs with potential applications in both prophylactic and therapeutic contexts [<xref rid="B44" ref-type="bibr">44</xref>, <xref rid="B45" ref-type="bibr">45</xref>].</p><p>In contrast, alternative approaches involved the design of a soluble Env protein that connected gp120 and gp41 by a flexible linker made of glycine and serine residues. Despite having a simpler structure than SOSIP, these proteins failed to primarily induce a neutralizing humoral immune response [<xref rid="B46" ref-type="bibr">46</xref>].</p><p>However, both preclinical and clinical studies demonstrated that Env struggles to elicit high Abs titers, with the anti-Env antibodies typically exhibiting shorter half-lives compared to those induced by other protein-based vaccines [<xref rid="B47" ref-type="bibr">47</xref>]. In addition, the humoral response triggered by Env immunogens neutralize only laboratory-adapted tier 1 viruses and/or the autologous virus harboring the Env variant used in the vaccine preparation, yet it does not extend to heterologous primary isolates [<xref rid="B34" ref-type="bibr">34</xref>]. This pattern has been validated through various comparative experiments involving both monomeric and native conformations of Env. While gp120 induces an adequate immune response, the resulting antibody tier is lower and declines faster than other immunogens, such as hemagglutinin [<xref rid="B48" ref-type="bibr">48</xref>, <xref rid="B49" ref-type="bibr">49</xref>]. This impairment of the immune system could be attributed to the signaling triggered by the binding between gp120 and CD4. In fact, many studies reported that gp120 interferes with B cell maturation and proliferation <italic toggle="yes">in vitro</italic> [<xref rid="B50" ref-type="bibr">50</xref>]. Moreover, the poor immunogenicity of Env proteins arises from their unique properties.</p><p>Conserved regions on Env proteins are shielded by a coating of glycans, and vulnerable sites are transiently exposed. Furthermore, Env sequences can change without compromising function, hastening the viral evasion from immune system detection [<xref rid="B51" ref-type="bibr">51</xref>].</p><p>Given the suboptimal immunogenic features of Env proteins, several adjuvants have been explored. Specifically, studies have been carried out to assess both their impact on the immune system and on the maintenance of the structural integrity of immunogens. To date, research uniformly concludes that adjuvants enhance the immunogenicity of the Env proteins; however, distinct adjuvants are required for trimers and monomeric forms of Env proteins [<xref rid="B51" ref-type="bibr">51</xref>].</p></sec></sec><sec id="sec3"><title>3. Vaccinal Approaches Based on the Structure of Anti-HIV Antibodies</title><p>Antibodies serve as a crucial immunological defense against infection, with NAbs playing a pivotal role in both the control of infections and for vaccine success. NAbs are naturally induced during HIV-1 infections and, when administered through passive transfer, they demonstrate the ability to protect animal models and affect ongoing HIV-1 infection in humans [<xref rid="B34" ref-type="bibr">34</xref>]. However, it is worth noting that about 10%&#8211;30% of HIV-1-infected individuals generate antibodies with broader activity, capable of neutralizing more than one strain [<xref rid="B52" ref-type="bibr">52</xref>], but only a small fraction of these subject is able to produce high levels of NAbs needed to block the infection [<xref rid="B53" ref-type="bibr">53</xref>]. This relatively low proportion of individuals with broadly neutralizing antibodies can be attributed to the unique characteristics of these antibodies. They undergo a complex maturation process, featuring somatic hypermutations (SHM) that can reach levels of up to 40%, and possess an elongated heavy chain complementary determining region 3 (CDRH3) [<xref rid="B43" ref-type="bibr">43</xref>]. Moreover, HIV has a glycan shell on its gp120, which serves as a protective barrier against recognition by the humoral system. The induction of antibodies against these glycans is exceptionally challenging because glycans are low immunogenic molecules. Furthermore, anti-HIV-1 glycan antibodies must specifically target the Env antigen while avoiding self-reactivity [<xref rid="B54" ref-type="bibr">54</xref>].</p><p>The quest for anti-HIV-1 NAbs began in the early 1990s, leading to the identification of first-generation NAbs, and subsequently, broader second-generation NAbs. This crucial breakthrough provided valuable insights into both the neutralizing humoral response and key sites of HIV-1. Through epitope mapping, researcher identified five major Abs binding sites: the CD4-binding site (CD4bs) [<xref rid="B55" ref-type="bibr">55</xref>&#8211;<xref rid="B57" ref-type="bibr">57</xref>], a viral glycan patch on gp120 [<xref rid="B58" ref-type="bibr">58</xref>], the MPER domain [<xref rid="B59" ref-type="bibr">59</xref>, <xref rid="B60" ref-type="bibr">60</xref>], the hypervariable gp120 V3 loop [<xref rid="B61" ref-type="bibr">61</xref>], and V1/V2 gp120 loop (<xref rid="fig1" ref-type="fig">Figure 1</xref>) [<xref rid="B59" ref-type="bibr">59</xref>].</p><p>Consequently, vaccinal strategies based on immunogens that mimic these targets were developed, but the outcomes were disappointing, as they failed to elicit a broad or potent cross-clade humoral response [<xref rid="B62" ref-type="bibr">62</xref>]. These suboptimal results can be attributed to the unique characteristics of the NAbs described earlier [<xref rid="B63" ref-type="bibr">63</xref>&#8211;<xref rid="B65" ref-type="bibr">65</xref>]. Interestingly, anti-HIV-1 Abs that show absent to low levels of neutralization exhibit higher somatic mutations than nonspecific Abs cloned from the same B cell pool [<xref rid="B34" ref-type="bibr">34</xref>, <xref rid="B66" ref-type="bibr">66</xref>]. However, it has been extensively observed that several mutations are necessary for achieving neutralizing activity [<xref rid="B67" ref-type="bibr">67</xref>&#8211;<xref rid="B69" ref-type="bibr">69</xref>], and that the level of SHM observed in HIV-1-specific Abs is higher compared to other chronic virus-specific Abs [<xref rid="B70" ref-type="bibr">70</xref>]. Hence, previous immunogens used to elicit bNAbs likely could not engage B cells expressing bNAb precursors and start their maturation [<xref rid="B34" ref-type="bibr">34</xref>].</p><p>Based on these observations, it was proposed to employ a series of vaccinations in a sequential manner. The purpose is to specifically target na&#239;ve B cell precursors and direct the immune response through multiple stages of development, mirroring the progression seen in a natural infection. To achieve this, a B cell-lineage vaccine design was developed.</p><sec id="sec3.1"><title>3.1. B Cell-Lineage Vaccine Design</title><p>B cell-lineage vaccine strategy targets bNAbs-precursor B cells to guide the maturation of these antibodies through stimulation with Env-based immunogens. These immunogens are carefully chosen to bind each maturation intermediates [<xref rid="B71" ref-type="bibr">71</xref>, <xref rid="B72" ref-type="bibr">72</xref>]. The initial step involves isolating a bNAb-producing B cell clone and sequencing its B cell receptors (BCRs) to identify related clonal members. The more clonal members identified, the easier it becomes to reconstruct the maturation history of the bNAb. However, because mature bNAbs undergo significant changes, especially the heavy (HC) and light chain (LC) CDR-3 regions, deducing the unmutated common ancestor (UCA) of the lineage can be challenging [<xref rid="B53" ref-type="bibr">53</xref>]. Computationally reconstructed B cell clonal genealogies play a fundamental role in studying Ab evolution and assisting in the design of HIV-1 vaccine. The design, based on UCA and the inferred ancestral intermediates, can be achieved by either germline-targeting, structure-based immunogen design, or mutation-guided immunogen design (<xref rid="fig2" ref-type="fig">Figure 2</xref>) [<xref rid="B53" ref-type="bibr">53</xref>].</p><p>Germline targeting entails selecting the best immunogen that binds the UCA. This priming step is critical, and the choice of the immunogen can be informed by longitudinal studies on HIV-1 positive patient defining the transmitted/founder (TF) virus or by the design the Env immunogen itself [<xref rid="B73" ref-type="bibr">73</xref>]. It has been observed that bNAb UCAs have limited binding affinity to most Env proteins, but may recognize the TF Env in some cases [<xref rid="B74" ref-type="bibr">74</xref>&#8211;<xref rid="B76" ref-type="bibr">76</xref>]. Alternatively, the immunogen can be engineered to enhance its binding avidity to UCA by screening Env variants library and gaining insights into the structure of the epitope. Both mutation-guided immunogen design and structure-based immunogen design contribute to this approach (<xref rid="fig2" ref-type="fig">Figure 2</xref>) [<xref rid="B53" ref-type="bibr">53</xref>]. An example of this strategy is the VRC01 class germline-based design. VRC01-class bNAbs stand out as the most potent and broad of all bNAbs discovered to date [<xref rid="B77" ref-type="bibr">77</xref>]. These antibodies specifically target the relatively conserved CD4-binding site epitope on the HIV-1 Env protein. They share a common HC V gene, VH1-202, which encodes a CDRH2 (complementary determining region 2, heavy chain) region that forms essential contacts with the CD4bs on Env. These HC are paired with a LC bearing a short five amino acid complementary determining region 3 (CDRL3) [<xref rid="B68" ref-type="bibr">68</xref>, <xref rid="B78" ref-type="bibr">78</xref>, <xref rid="B79" ref-type="bibr">79</xref>]. Importantly, VRC01-class precursors are relatively more common compared to other bNAbs precursors. In fact, they have been found in many HIV-1 patients at levels sufficient for germline targeting [<xref rid="B80" ref-type="bibr">80</xref>, <xref rid="B81" ref-type="bibr">81</xref>]. Antibodies within this VRC01 class, such as VRC01 itself [<xref rid="B78" ref-type="bibr">78</xref>], 3BNC60 [<xref rid="B68" ref-type="bibr">68</xref>], 12A12 [<xref rid="B68" ref-type="bibr">68</xref>], N6 (broadest HIV-1 bNAb described to date [<xref rid="B79" ref-type="bibr">79</xref>]), have all been isolated from different patients. As expected, VRC01-class bNAbs showed a high level of SHM, including insertions and deletions, to achieve their remarkable activity and broad spectrum of neutralization. For the constitution of a vaccine capable of eliciting Abs like these, the best candidates developed so far were the engineered outer domain of gp120, eOD-GT8 [<xref rid="B71" ref-type="bibr">71</xref>], the glycan-deleted derivatives of clade C, 426c Env [<xref rid="B82" ref-type="bibr">82</xref>], and, most recently, two different versions of the near-native trimers BG505 SOSIP: BG505 SOSIP.v4.1-GT1 [<xref rid="B83" ref-type="bibr">83</xref>] and BG505 SOSIP.v4.1-GT1.2 [<xref rid="B84" ref-type="bibr">84</xref>]. The first three candidates have now been evaluated in human clinical trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT05414786" ext-link-type="uri">NCT05414786</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT05471076" ext-link-type="uri">NCT05471076</ext-link>, and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04224701" ext-link-type="uri">NCT04224701</ext-link>, respectively). It was described that both eOD-GT8 and 426c Env immunogens primes VRC01-class precursors in knock-in (KI) mouse models [<xref rid="B85" ref-type="bibr">85</xref>, <xref rid="B86" ref-type="bibr">86</xref>]; however, they engage different bNAbs precursors [<xref rid="B87" ref-type="bibr">87</xref>]. Despite their potential, these two immunogens are not able to select for insertion, and only eOD-GT8 is selected for single aa deletion in CDRL1 [<xref rid="B88" ref-type="bibr">88</xref>]. Instead, it has been proposed that Env trimer immunogens can favor improbable insertions [<xref rid="B89" ref-type="bibr">89</xref>]. The design of BG505 SOSIP.v4.1-germline-targeting trimer 1 is based on the BG505 SOSIP.664 and it engages both VRC01 and V2-apex germline-precursors. VRC01, PGV19, and NIH45-46 germlines were engaged with nanomolar affinity. However, this immunogen was not able to bind to other Abs of the VRC01-class [<xref rid="B83" ref-type="bibr">83</xref>]. A second modified version of BG505 SOSIP.v4.1-GT1, BG505 SOSIP.v4.1-GT1.2, has recently been developed to broaden VRC01-class precursor recognition. Maturation of the VRC01-class Abs has been reported, including rare multiresidue insertions that recapitulate those observed in VRC01-class bNAbs, as well as deletions and glycine substitutions [<xref rid="B84" ref-type="bibr">84</xref>].</p><p>Mutation-guided immunogen design aims to identify the improbable mutations in bNAbs that are critical for broad neutralization and convert this information into the design of immunogens capable of binding na&#239;ve or intermediated BCRs with the desired rare mutations [<xref rid="B90" ref-type="bibr">90</xref>].</p><p>Structure-based immunogen design is based on the characterization of bNAbs-Env complexes on an atomic level. This allows to model the Env immunogen around the Ab and its precursors to increase the binding by introducing epitope modifications. This approach is used to guide all stages of the vaccine design strategy [<xref rid="B91" ref-type="bibr">91</xref>]. An example of this approach based on V3 glycan-targeted bNAbs is PGT121. PGT121 is the best-characterized NAb exhibiting a high level of SHM which distinguishes it from other NAbs derived from the same precursor. It targets the region close to the V3 loop that is heavily glycosylated [<xref rid="B92" ref-type="bibr">92</xref>], and recognizes glycans at N301, N137, and N156, as opposite to other antibodies belonging to the same family that are highly dependent on N332 [<xref rid="B93" ref-type="bibr">93</xref>, <xref rid="B94" ref-type="bibr">94</xref>]. Furthermore, while the precise identification of the actual UCAs of PGT121 class remains unknown, the presence of multiple members within the PGT121 lineage allows for the prediction of a PGT121 germline [<xref rid="B93" ref-type="bibr">93</xref>]. A structure-based approach was used to identify Env trimers variants with affinity for PGT121 germline-reverted precursors, resulting in an expansion of these precursors in PGT121 KI mice [<xref rid="B95" ref-type="bibr">95</xref>]. Moreover, sequential immunization with specifically Env designed immunogens induced NAbs maturation [<xref rid="B96" ref-type="bibr">96</xref>]. Following studies in animal models such as mice, rabbits, and rhesus macaques, showed that RC1 (engineered SOSIP Env trimers) and RC1-4fill (RC1 variant with glycans add to gp120 positions 230, 241, 289, and 344) induce clonal expansion of B cell expressing antibodies similar to inferred germline precursors of bNAbs targeting the V3-glycan patch [<xref rid="B97" ref-type="bibr">97</xref>]. The boosting experiment conducted on rhesus macaques, who were initially primed with RC1-4fill VLP, revealed that the immunization strategy utilizing the modified native-like Env trimer (SOSIP) resulted in the production of limited quantities of heterologous NAbs. Additionally, there were reports of off-target activity exhibited by these Abs [<xref rid="B96" ref-type="bibr">96</xref>].</p></sec><sec id="sec3.2"><title>3.2. Anti-Idiotype Antibodies</title><p>An additional vaccine approach against HIV-1 infection involves manipulating the immune network by utilizing anti-idiotype (anti-Id) Abs. Over the years, different pieces of evidence have suggested that idiotype&#8211;anti-idiotype interactions play a role in regulating immune responses for multiple infectious diseases. The underlying concept is that the idiotype region of any antibody is inherently antigenic: antibodies generated against the idiotype of the primary antibody molecule can structurally resemble the original antigen as they carry its &#8220;internal image&#8221; [<xref rid="B98" ref-type="bibr">98</xref>]. This set of internal image Abs can then be used as immunogens to induce protective immunity. Specifically, anti-Id Abs can serve as prophylactic vaccines themselves, or be employed to enhance existing humoral and cellular immune responses against selected epitopes (<xref rid="fig1" ref-type="fig">Figure 1</xref>) [<xref rid="B99" ref-type="bibr">99</xref>].</p><p>The use of anti-Id Abs as surrogate antigens has been shown to effectively stimulate a potential immune response that could confer protection against HIV-1. Murine monoclonal antibodies (mAbs) specific to p24, an abundant viral protein involved in HIV-1 assembly and maturation [<xref rid="B100" ref-type="bibr">100</xref>], were used to generate anti-Id Abs. Among these, TR009, an anti-Id Ab of 076&#8201;C, a murine mAb directed against p24, was found to recognize a common interspecies idiotype associated with anti-HIV-1 response. Immunizing rats with TR009 resulted in the induction of substantial antibody levels against recombinant p24 protein [<xref rid="B99" ref-type="bibr">99</xref>]. Another comparable approach was performed generating a series of overlapping anti-Id Abs targeting two anti-p24 murine mAbs, VIC5 and VIC6. Mice were immunized with a combination of the anti-Id Abs, which only slightly induced their reactivity to p24 antigen [<xref rid="B101" ref-type="bibr">101</xref>].</p><p>As previously mentioned, gp120 is a key target of anti-HIV-1 humoral responses and several vaccinal approaches based on this protein have been studied to induce a broad protective response. However, as already described above, none of the vaccines developed so far have reached this aim. To overcome this challenge, researchers have explored the concept of idiotypic mimicry employing antibodies directed against the idiotypes of antibodies able to bind CD4bs on gp120. A study provided a proof of concept for this strategy, in fact, antibodies directed against the idiotype of anti-gp120 immunoglobulins were used to mimic the conformation of CD4bs. Using these antibodies in the immunization of rabbits, antibodies capable of recognizing recombinant and cellular human CD4 were induced (<xref rid="fig1" ref-type="fig">Figure 1</xref>) [<xref rid="B102" ref-type="bibr">102</xref>].</p><p>The mAb 3C9, directed against the idiotype of human anti-CD4bs/gp120 Abs, was used to elicit bNAbs in na&#239;ve, non-HIV-1-infected monkeys [<xref rid="B103" ref-type="bibr">103</xref>]. However, the approach did not rely on anti-Id Ab mimicry, as 3C9 did not represent the internal image of the CD4 attachment site of gp120. Instead, 3C9 was found to define a marker on B cells producing anti-gp120 NAbs, thereby stimulating their synthesis. The study also introduced the concept that the ability of an anti-Id Ab to elicit antigen-specific immune responses depends on the presence of a common B-cell repertoire that recognizes both the antigen and anti-Id Abs in target animals [<xref rid="B103" ref-type="bibr">103</xref>].</p><p>An alternative strategy was based on the search of the anti-idiotype of the antibodies of long-term non-progressor (LTNP) patients, HIV-positive subjects able to maintain high CD4 and CD8 levels without specific therapy [<xref rid="B104" ref-type="bibr">104</xref>, <xref rid="B105" ref-type="bibr">105</xref>]. Anti-CD4bs/gp120 IgG were purified from LTNP patients and used to immunize mice. This procedure allowed the identification of two anti-Id Abs, named P1 and P2, able to recognize the idiotype of both anti-CD4bs LTNP IgG and of one of the most broadly neutralizing human mAbs, IgG b12. Moreover, rabbit sera, obtained after immunization with P1, exhibited neutralizing activity of over 80% against HXB2 pseudovirus, and few of them were capable of neutralizing HIV-1-MN pseudovirus as well [<xref rid="B104" ref-type="bibr">104</xref>]</p><p>Studies on 1F7 idiotypes have revealed the significant role of anti-Id Abs as immune network regulators in the context of chronic infections. The 1F7 mAb is derived from mice immunized with immunoglobulin pool from several HIV-1-infected individuals [<xref rid="B106" ref-type="bibr">106</xref>]. Further investigations have demonstrated that the idiotype/clonotype 1F7 is commonly found in human monoclonal anti-gp120 and anti-p24 Abs, as well as in anti-HIV-1 human sera [<xref rid="B107" ref-type="bibr">107</xref>]. Various pieces of evidence support the biological relevance of the 1F7 idiotype in HIV-1 infection. A serological auto-anti-idiotypic humoral immune response to the 1F7 idiotype was observed using a specific peptide mimicking the idiotypic region [<xref rid="B108" ref-type="bibr">108</xref>, <xref rid="B109" ref-type="bibr">109</xref>]. Anti-Id mAb 1F7 was shown to selectively inhibit anti-HIV-1 cytotoxic CD8<sup>+</sup> T cells against uninfected CD4<sup>+</sup> T cells, potentially contributing to the prevention of CD4<sup>+</sup> depletion and disease progression in human HIV-1 infection [<xref rid="B110" ref-type="bibr">110</xref>]. Assessments of the 1F7 idiotype expression and evolution in patients' sera during acute and chronic HIV-1 infection have led to the conclusion that 1F7 expression is associated with a form of clonal dominance. This phenomenon appears to limit the development of NAbs against circulating infecting strains of HIV-1 [<xref rid="B111" ref-type="bibr">111</xref>]. bNAbs against HIV-1 have been found to express the 1F7 idiotype, suggesting that the same idiotypic axis, which underlies clonal dominance and original antigenic sin, also facilitates antibody evolution toward highly mutated progeny capable of neutralizing diverse strains of HIV-1 [<xref rid="B111" ref-type="bibr">111</xref>]. Understanding how to selectively exploit this axis to prime for the development of bNAbs prior to viral exposure is considered a promising strategy for the development of a more effective HIV-1 vaccination [<xref rid="B111" ref-type="bibr">111</xref>].</p><p>As previously mentioned, engaging na&#239;ve B cells capable of generating bNAbs is considered essential for the development of a successful HIV-1 vaccine. However, the approach of germline targeting using modified Env immunogens has faced limitations, particularly in terms of activating off-target immune responses [<xref rid="B112" ref-type="bibr">112</xref>]. Recent studies have shown that anti-Id Abs could recognize and activate bNAbs precursor B cells <italic toggle="yes">in vivo</italic>, making them a viable alternative or complement to Env immunogens. Anti-Id Abs specific to the inferred germline version of HIV-1 bNAb b12 (iglb12) were used to identify and analyze na&#239;ve B cells expressing iglb12-like BCRs. Immunization of transgenic mice with one of these anti-Id Abs resulted in the proliferation of transgenic murine B cells expressing the iglb12 heavy chain <italic toggle="yes">in vivo</italic>. Some instances of deletion and anergy were reported within this B cell population [<xref rid="B113" ref-type="bibr">113</xref>].</p><p>In an alternative approach, the anti-Id Ab iv8 was used to selectively expand a specific population of B cells, giving them a competitive advantage. This anti-Id Ab exhibited high affinity for VRC01-class precursor BCRs [<xref rid="B112" ref-type="bibr">112</xref>]. iv8 induced the expansion and maturation of B cells expressing VRC01-class Abs <italic toggle="yes">in vivo</italic>, resulting in serological responses targeting the CD4bs on the Env without activating B cell clones that produce off-target responses to Env [<xref rid="B112" ref-type="bibr">112</xref>].</p><p>An improved targeting strategy was implemented to optimize VRC01 precursors recognition. Initially, new anti-Id mAbs that bind with high-affinity multiple VRC01 precursors were developed. However, subsequent analysis revealed that these mAbs selectively recognize BCRs with either VRC01-class LCs featuring a 5-aa CDRL3 or with heavy chains derived from VH1-2<sup><italic toggle="yes">&#8727;</italic></sup>02, but not BCRs possessing both characteristics [<xref rid="B114" ref-type="bibr">114</xref>]. The engagement and activation of B cells expressing VRC01 precursor-like BCRs were obtained through the engineering of a bispecific anti-idiotypic molecules derived from the anti-Id mAb iv9, that preferentially recognizes the VH1-2<sup><italic toggle="yes">&#8727;</italic></sup>02 heavy chain, and the anti-Id mAb iv4 which tends to recognize LCs with 5-aa CDRL3 [<xref rid="B114" ref-type="bibr">114</xref>]. This bispecific anti-Id mAb iv4/iv9 activates iGL-VRC01 B cells <italic toggle="yes">in vitro</italic>, and in a murine adoptive transfer model, it displays superior engagement and expansion of VRC01 precursor B cells compared to iv4 or iv9 alone as Fab fragments [<xref rid="B114" ref-type="bibr">114</xref>].</p><p>Overall, these findings highlight the significance of the anti-Id mAbs as valuable immunogens for developing HIV-1, particularly for activating specific B cell lineages capable of producing protective antibodies.</p></sec></sec><sec id="sec4"><title>4. <italic toggle="yes">In Silico</italic> Approaches for the T Lymphocytes Induction</title><p>Considering the continuous and constant improvement involving bioinformatic tools in these years, <italic toggle="yes">in silico</italic> analysis has been widely employed to study and develop immunogens. The use of these tools has previously been discussed in the context of studying immunogens based on the anti-HIV antibodies. Moreover, several studies have highlighted the importance of eliciting a T-cell response during HIV infection. Consequently, many vaccine approaches have been specifically directed toward achieving this objective.</p><p>One of the first strategies for the identification of cross-subtype HIV-1 immunogens was based on the individuation of conserved and promiscuous class II HLA-restricted T-cell epitopes from an HIV-1 Env sequences database. Following this, a set of &#8220;immunogenic consensus&#8221; was formulated, with some being synthesized and employed in <italic toggle="yes">in vitro</italic> systems, showing their immunogenicity. Consequently, the best candidates, most immunogenic and highly conserved, across a great number of HIV strains molecules were included in a vaccine preparation (the GAIA vaccine). Unfortunately, preclinical studies have not been conducted so far [<xref rid="B115" ref-type="bibr">115</xref>&#8211;<xref rid="B117" ref-type="bibr">117</xref>].</p><p>Another approach was used for the design of an mRNA vaccine based on epitopes of HIV-1 recognized by B- and T-cells. In this study, five HIV surface proteins were identified from the literature and, through bioinformatic tools, the most immunogenic epitopes able to activate humoral and cellular immune responses were found. Moreover, through <italic toggle="yes">in silico</italic> analysis, it was possible to study the complete vaccine preparation, and the immunological simulation revealed its capacity to elicit both innate and adaptive immune response. Using specific bioinformatic tools, the vaccine was also demonstrated to be able to establish memory cells upon exposure and to determine the production of chemokines responsible for the increasing of B cell and humoral responses [<xref rid="B118" ref-type="bibr">118</xref>].</p><p>Another bioinformatic study was based on the identification of specific anchor residue motifs in the primary amino acid sequence of the target pathogen involved in the binding to classes I and II HLA. The general idea for the vaccine constitution is the identification of conserved regions of pathogens and on the affinity prediction between prospective peptides and HLA molecules. Moreover, considering the high variability of HLA polymorphisms, peptides that could bind multiple HLA type were further studied to encompass the global population. When applied to HIV sequences present in the Los Alamos database for cytotoxic T lymphocyte (HTL) epitopes, the overall population coverage was about 98% using 17 epitopes. Epitopes immunogenicity was confirmed <italic toggle="yes">in vivo</italic> using HLA transgenic mice, and <italic toggle="yes">in vitro</italic> using PBMC-derived sera samples from HIV-1 exposed individuals [<xref rid="B119" ref-type="bibr">119</xref>]. Moreover, this strategy was improved by the application of a specific algorithm called TEPITOPE. It allowed the identification of a set of 18 HLA-DR binding CD4 T-cell epitopes derived from the whole clade B HIV-1 consensus protein-coding genome. All the selected epitopes were recognized by PBMC from HIV-1 infected patients [<xref rid="B120" ref-type="bibr">120</xref>]. These epitopes were used for the development of a DNA vaccine called HIVBr18, which elicit broad, polyfunctional, and long-living CD4<sup>+</sup> T cell responses in BALB/c and HLA class II transgenic mice [<xref rid="B121" ref-type="bibr">121</xref>, <xref rid="B122" ref-type="bibr">122</xref>]. Similar results were observed in rhesus macaques, where robust and predominantly polyfunctional CD4<sup>+</sup> T cell responses were observed in all animals for 13 out of the 18 epitopes [<xref rid="B123" ref-type="bibr">123</xref>]. Overall, these studies establish the proof of concept that vaccines based on promiscuous and multiple T cell have the potential to induce immune responses with relevant breadth and depth. This represents an additional tool for the development of clinical studies.</p></sec><sec id="sec5"><title>5. Alternative Vaccination Strategies Based on Vectors</title><p>For the constitution of an effective vaccine, the selection of an appropriate immunogen to stimulate a strong, durable, and neutralizing immune response is undoubtedly a pivotal consideration. Nonetheless, there are additional crucial factors to consider, such as how diverse immunogens are presented to the immune system. Presently, vaccines have the potential to be created exclusively from the genetic materials responsible for encoding the desired immunogens. This innovative approach exploits the utilization of vectors, which encompass modified bacteria, viruses, plasmid DNA, RNA, or sequences from pathogens, serving as vehicles to deliver the target antigen [<xref rid="B124" ref-type="bibr">124</xref>].</p><p>In this section, we will focus on viral vectors based on DNA or RNA viruses, which found substantial application in clinical trials for developing vaccines targeting HIV-1. These vector platforms have emerged as the predominant choice in this regard (<xref rid="tab2" ref-type="table">Table 2</xref>).</p><sec id="sec5.1"><title>5.1. DNA Viruses</title><sec id="sec5.1.1"><title>5.1.1. Adenovirus Vectors</title><p>Adenoviral vectors (AdV) are probably the most known and tested platform used to carry an exogenous sequence encoding for an immunogen for vaccinal purposes and gene therapy [<xref rid="B139" ref-type="bibr">139</xref>]. To avoid potential risks related to recombination, which may enhance its pathogenicity, replication-defective (RD) human adenovirus serotype 5 (HAd5)-based vectors have been widely used in various vaccine trials [<xref rid="B140" ref-type="bibr">140</xref>]. The first proof of concept human clinical trials for HIV-1 prevention using HAd5V were carried out through the STEP trial (HVNT 502). This trial took place in geographical areas where clade B stands as the predominant subtype. Recently, a related study called Phambili trial (HVNT 503) was conducted in South Africa, where clade C is the prevailing subtype. Both trials assessed the efficacy of a vaccine containing three HAd5V able to express three HIV-1 proteins clade B (Gag, Pol, and Nef) (<xref rid="tab1" ref-type="table">Table 1</xref>). Unfortunately, they were both stopped due to ineffectiveness: HIV acquisition appeared to be higher among patients with a preexisting anti-HAd5V antibody titer [<xref rid="B121" ref-type="bibr">121</xref>]. Despite the absence of definitive evidence, this phenomenon could be explained by the fact that vaccine can stimulate preexisting anti-HAd5V-specific CD4 T cells, thereby increasing the pool of cells permissible to HIV infection [<xref rid="B121" ref-type="bibr">121</xref>].</p><p>Given that approximately 90% of individuals possess existing immunity against HAd5 [<xref rid="B139" ref-type="bibr">139</xref>, <xref rid="B140" ref-type="bibr">140</xref>] alternative AdVs utilizing fewer common serotypes, such as HAd26 and HAd35 have been formulated [<xref rid="B127" ref-type="bibr">127</xref>, <xref rid="B130" ref-type="bibr">130</xref>]. After the aforementioned unsatisfactory results, these AdVs have mostly been associated with the advancement and evaluation of mosaic vaccines.</p><p>This last approach involves the development of a multivalent HIV vaccine utilizing a HAd26V-based (or Modified Vaccinia Ankara (MVA) based) vector. This vector encodes mosaic immunogens that have been computationally designed to trigger a neutralizing response against several HIV isolates [<xref rid="B141" ref-type="bibr">141</xref>]. Briefly, fragments from specific HIV-1 protein regions were designed using mathematical models, then combined to amplify the coverage of epitopes that T and B cells recognize. Moreover, it was demonstrated that a boost in the HAd26V-based immunization protocol with adjuvanted recombinant Env protein led to an increase in the neutralizing response in rhesus monkeys [<xref rid="B142" ref-type="bibr">142</xref>]. The APPROACH study was the first clinical trial aimed at evaluating the immunogenicity of a mosaic vaccine regime in order to prevent HIV-1 [<xref rid="B143" ref-type="bibr">143</xref>]. This pioneering trial not only verified the safety and tolerability of these formulations but also demonstrated the capacity to elicit antibodies directed specifically against the same HIV clade featured in the immunization. Nevertheless, the neutralizing activity was discernible solely against tier 1 HIV-1 isolates [<xref rid="B144" ref-type="bibr">144</xref>]. Starting from these important data, subsequent clinical trials were conducted to enhance the immunogenicity of these formulations, employing diverse combinations of immunization protocols [<xref rid="B145" ref-type="bibr">145</xref>] Regrettably, the MOSAICO phase III trial (HPX3002/HVTN706), conducted among transgender individuals and men who have sex with men, had to be prematurely halted due to its failure in preventing HIV infection.</p><p>This lack of efficacy was further corroborated by the phase IIb trial IMBOKODO (HPX2008/HVTN 705) that followed the same regimen and was conducted among young Sub-Saharan women [<xref rid="B146" ref-type="bibr">146</xref>, <xref rid="B147" ref-type="bibr">147</xref>].</p><p>From this perspective, a distinct adenovirus derived from chimpanzees, specifically the Y25 strain, is currently under examination for its potential in vaccine therapy. One key advantage is its lack of connection to preexisting immunity in humans [<xref rid="B148" ref-type="bibr">148</xref>]. This vector, termed ChAdOx1, recently gained attention as a potential platform for COVID-19 vaccine development. Ewer et al. [<xref rid="B149" ref-type="bibr">149</xref>] demonstrated the elicitation of NAbs, with subsequent enhancement following booster doses. Outcomes are on the horizon for the development of an HIV-1 vaccine. ChAdOx1 has recently been within the context of the mosaic vaccine strategy HIV-1 prevention, as evidenced by studies such as HIV-CORE 0052 and HIV-CORE 006 (<xref rid="tab3" ref-type="table">Table 3</xref>).</p></sec><sec id="sec5.1.2"><title>5.1.2. Adeno-Associated Viral Vectors</title><p>Adeno-associated viral vectors (AAVs) have emerged as the preferred choice for both gene therapy and vaccine development due to their remarkable safety profile, minimal immunogenic characteristics, broad tropism (including postmitotic cells), and crucial ability to induce sustained Abs expression with a single administration owing to their episomal structure [<xref rid="B140" ref-type="bibr">140</xref>, <xref rid="B153" ref-type="bibr">153</xref>]. AAVs have demonstrated lower immunogenicity than other viral vector platforms, although they retain the potential to elicit a dose-dependent immune response [<xref rid="B154" ref-type="bibr">154</xref>]. Despite the evident benefits outweigh the drawbacks, there is only one documented proof of concept clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01937455" ext-link-type="uri">NCT01937455</ext-link>) involving human subjects that used AAV for HIV-1 prevention in healthy volunteers [<xref rid="B129" ref-type="bibr">129</xref>]. This trial, which reached completion, involved the testing of different dosages of a recombinant AAV (rAAV) encoding for PG9, a human anti-HIV-1 broad neutralizing antibody (rAAV1-PG9DP) aiming to elicit a sustained expression of a specific immune response to prevent HIV infection. The vaccine proved to be safe, with PG9 detected in the sera of only four subjects, albeit at a low level [<xref rid="B129" ref-type="bibr">129</xref>].</p><p>Whether intended for gene therapy or as a platform for vaccines, the consensus among scientists is that more comprehensive research is imperative, employing a multidisciplinary approach to understand the innate immune response triggered by these vectors. Furthermore, an assessment of potential acute or chronic toxicity remains a necessary step [<xref rid="B154" ref-type="bibr">154</xref>].</p></sec><sec id="sec5.1.3"><title>5.1.3. Pox Virus Vectors</title><p>MVA is a promising type of nonreplicant poxvirus developed as a vector vaccine in 1975 [<xref rid="B1" ref-type="bibr">1</xref>]. The viral distinctive ability to replicate within the host cytoplasm, coupled with its robust safety profile and broad tropism, makes the vaccinia virus an excellent foundation for vector-based vaccines. Approximately 15 years after MVA discovery, other nonreplicating vectors progressed, notably the highly attenuated vaccinia virus (NYVAC), and a canarypox virus (ALVAC) [<xref rid="B1" ref-type="bibr">1</xref>]. The latter is currently the most frequently used vector in HIV-1 clinical trials, along with HAd26 and MVA [<xref rid="B1" ref-type="bibr">1</xref>]. The most successful HIV-1 clinical trial, RV144 (or Thai trial), used the ALVAC vector expressing gp120 (subtype E) linking to gp41 (subtype B), gag and protease (subtype B)- for priming, followed by a booster administrating recombinant gp120 clade B protein/Alum (AIDSVAX&#174; B/E) [<xref rid="B155" ref-type="bibr">155</xref>], resulting in a 31.4% efficacy rate [<xref rid="B156" ref-type="bibr">156</xref>]. Subsequent clinical trials were carried out in South Africa where HVTN 097 replicated the RV144 regimen and showcased comparable results; HVTN 100 and HVTN 702 introduced modifications related to the HIV-1 subtype selected for expressing immunogens and adjuvant employed. Notably, serotype C gp120 and MF59 were adopted in these trials. The decision to use serotype C was based on epidemiological study in South Africa, representing the first attempt at a regional-based improvement of the vaccine. Despite observing elevated levels of both humoral and cellular immune response in HVTN 100 (albeit distinct from those studied in RV144), the HVTN 702 trial, which sought to assess the effectiveness of this version of the vaccine, was prematurely terminated due to inconclusive results [<xref rid="B135" ref-type="bibr">135</xref>, <xref rid="B136" ref-type="bibr">136</xref>, <xref rid="B157" ref-type="bibr">157</xref>].</p><p>It becomes imperative to consider various factors such as the use of different adjuvants, the genetic diversity of Env gp120 genes, and the difference in HIV-1 incidence between South Africa and Thailand when embarking on the development of a preventive HIV-1 vaccine. This holds true even when employing the same type of vector and recombinant protein [<xref rid="B143" ref-type="bibr">143</xref>].</p><p>Being the sole successful HIV-1 clinical trial in preventing infection acquisition up to now, RV144 prompted two other studies (RV305 [<xref rid="B131" ref-type="bibr">131</xref>] and RV306 [<xref rid="B134" ref-type="bibr">134</xref>]) to explore the potential of post-trial immunizations for sustaining protective effects. RV305 and RV306 aimed to administer additional doses of ALVAC and AIDSVAX&#174; B/E, either individually or in combination, 6&#8211;8 years or 12&#8211;15&#8211;18 months after the conclusion of RV144 trial, respectively [<xref rid="B131" ref-type="bibr">131</xref>, <xref rid="B134" ref-type="bibr">134</xref>]. In contrast to the protocol regimen used in RV305, RV306 demonstrated that a booster can enhance the immune response within a year of RV144 vaccination regimen. Conversely, HVTN 702, mentioned earlier, yielded contrasting outcomes compared to RV306. Despite showing a 12-month booster, it failed to produce a statistically significant protective effect. Consequently, it is still uncertain whether the amplified responses observed in RV306 will translate into virus protection [<xref rid="B158" ref-type="bibr">158</xref>].</p></sec></sec><sec id="sec5.2"><title>5.2. RNA Viruses</title><sec id="sec5.2.1"><title>5.2.1. mRNA Vector</title><p>The RNA technique is a recent type of genetic vaccine that holds the distinctive ability to deliver protein-coding sequence as messenger RNA (mRNA) [<xref rid="B159" ref-type="bibr">159</xref>]. The advent of the COVID-19 pandemic provided a global platform for evaluating and acknowledging this novel vaccine category, which is encapsulated in lipid nanoparticles to protect the molecule from degradation [<xref rid="B159" ref-type="bibr">159</xref>, <xref rid="B160" ref-type="bibr">160</xref>]. mRNA as a vector offers greater efficiency compared to conventional vaccination strategies, largely due to its nonintegrating properties, its ease manipulation, and its extensive adaptability in generating various immunogens related to the pathogen under investigation [<xref rid="B161" ref-type="bibr">161</xref>]. Moreover, immunogens created from inactivated virus can be different from their native conformation, whereas subunit vaccines produced by nonhuman cell lines could introduce post-translational modifications that result in antigens bearing altered conformations [<xref rid="B153" ref-type="bibr">153</xref>]. Recently, the in-progress HVNT 302 clinical trial, situated in the United States, is evaluating three novel mRNA-based HIV-1 vaccines whose findings are expected by the end of 2023. The vaccine regimens use three versions of the stabilized native-like trimer [<xref rid="B95" ref-type="bibr">95</xref>]: the BG505 MD39.9 mRNA, the BG505 MD39.9 gp151 mRNA, and the BG505 MD39.3 gp151 CD4KO mRNA. Through these vaccines, the aim is to assess their safety and ability to elicit autologous NAbs.</p><p>In addition to previous applications, mRNA is also raising interest for its potential use in therapeutic clinical trials. In general, therapeutic vaccines have the unique characteristic to transform host immunity of chronic disease patients by either enhancing the T cell-mediated immune response or by stimulating B cells capable of producing specific Abs improving the humoral immunity [<xref rid="B162" ref-type="bibr">162</xref>, <xref rid="B163" ref-type="bibr">163</xref>]. The reconsideration of these vaccines has lately been prompted by the failure of all HIV-1 prophylactic vaccine clinical trials, the rise of chronic diseases, and the development of drug resistances [<xref rid="B162" ref-type="bibr">162</xref>]. Although these vaccines could provide long-term immune memory to a large number of HIV-infected people, the virus exhibits few qualities that make it a challenging target for therapy success. Indeed, HIV-1 latency, Env proteins wide variability, viral genome diversity, and its rapid evolution make the progress of a therapeutic vaccine ambitious [<xref rid="B162" ref-type="bibr">162</xref>, <xref rid="B164" ref-type="bibr">164</xref>]. Despite the difficulties, various therapeutic vaccine trials have been performed and few recent promising vaccines have completed at least phase I. Among them, the first-in-human dose-escalating clinical trial used naked mRNA targeting dendritic cells. It employed a novel HIV-1 immunogen (HTI) that encodes essential target epitopes found on Gag, Pol, Vif, and Nef (<xref rid="tab1" ref-type="table">Table 1</xref>). The trial was performed in HIV-1 infected adults undergoing combined ART (cART) treatment (phase I iHIVARNA [<xref rid="B137" ref-type="bibr">137</xref>]). Results indicated that only the group receiving the highest dosage exhibited any effect on their T-cell response. All the other groups showed no observable changes. Given the proof of its safety, the same vaccine approach was replicated in a subsequent phase II trial, named iHIVARNA, which involved HIV-1 patients receiving cART, with the intention of discontinuing medication upon completion of the regimen [<xref rid="B138" ref-type="bibr">138</xref>]. However, the iHIVARNA product encountered an error in the RNA sequence. Unintentionally, a second start codon ahead of the HTI immunogen coding sequence was present, forcing the study to end earlier than expected. The consequences of this mistake would probably affect the expression of HTI protein, though the extent is still unknown [<xref rid="B138" ref-type="bibr">138</xref>].</p><p>Even if not in-depth discussed in this review, it is crucial to mention additional promising therapeutic vaccines that use different techniques than mRNA, such as peptide-based vaccines (VAC-3S, IPROTECT1, Vacc-4x) and DNA-based vaccines (VRC 101 study, DermaVir, BCN 01) [<xref rid="B165" ref-type="bibr">165</xref>]. Regardless of strategy, the ultimate objective of all therapeutic clinical trials is to induce CD8<sup>+</sup> T cell-mediated responses, with particular attention to memory responses required for guaranteeing long-lasting immunity [<xref rid="B165" ref-type="bibr">165</xref>].</p></sec></sec></sec><sec id="sec6"><title>6. Conclusions</title><p>Vaccines hold the potential to elicit a protective response that ideally should be enduring. In the context of HIV-1, achieving this goal has remained elusive due to the peculiar biological characteristics of the virus that entailed the lack of success in numerous clinical trials conducted over the years. Nevertheless, the various experimental vaccination strategies, employing different formulations and approaches, have provided invaluable insight into the virus and its ability to trigger a humoral immune response. These insights are pivotal for the creation of vaccines aimed at significantly reducing the prevalence of HIV-1 infections.</p><p>As explored in this review, while traditional vaccination methods did not yield the desired outcomes, they did provide a pathway to comprehend the fundamental traits of HIV-1 Env protein and grasp its vulnerabilities. This understanding subsequently paved the way for the development of the most promising HIV-1 trial (RV144), which achieved a 31.4% efficacy rate. Despite its modest success rate, this trial marks a pivotal juncture in the pursuit of an effective vaccine for HIV-1, underscoring the importance of mirroring the evolutionary trajectory of the viral infection observed <italic toggle="yes">in vivo</italic>.</p><p>This notion was further explored in investigative studies that focused on targeting the na&#239;ve precursors and direct the humoral immune response through multiple maturation phases, mirroring the progression seen in natural infection. The identification of monoclonal neutralizing antibodies and anti-idiotypes played a pivotal role in shaping the development of this strategy. The advancements in antibody-to-vaccine and the combination of <italic toggle="yes">in silico</italic> and <italic toggle="yes">in vitro</italic> approaches are promising; however, numerous facets of this strategy are yet to be conclusively defined.</p><p>Vaccines designed to induce broadly neutralizing antibodies must trigger all different components of the immune response, as the CD4<sup>+</sup> TFH cell response stimulates high levels of highly mutated bNAbs.</p><p>Numerous studies have examined the activation of T lymphocytes as a means of controlling and preventing infection, a perspective underscored by elite controller HIV-1-infected patients and diverse animal models. Nevertheless, clinical trials that aimed to induce T-cell responses experience setbacks, failing both in infection prevention and viral load management [<xref rid="B166" ref-type="bibr">166</xref>, <xref rid="B167" ref-type="bibr">167</xref>]. Other investigations have explored the role of the innate immune system in constraining HIV-1, with a recent instance involving the examination of Toll-like receptor (TRL) agonists in conjunction with neutralizing antibodies for infection treatment or vaccination formulation [<xref rid="B168" ref-type="bibr">168</xref>, <xref rid="B169" ref-type="bibr">169</xref>]. However, conclusive outcomes remain pending.</p></sec><sec id="sec7"><title>7. Future Recommendation</title><p>Although many strategies have been designed and tested, an effective anti-HIV-1 vaccine is still not available. These failures reflect the complexity of the virus itself and, even more, the interaction with its host. Vaccine development must take into account host-related factors that affect immune responses to HIV-1 vaccination and vaccine efficacy. Such factors encompass immunogenetics, body mass index, and other demographic variables. Additionally, the choice of vector and adjuvant within the vaccination protocol significantly impacts the potential immune response of recipients [<xref rid="B157" ref-type="bibr">157</xref>].</p><p>Despite the persistent effort to formulate an effective anti-HIV-1 strategy, the desired objective has yet to be attained. This underscores the presence of unidentified elements, but new insights from immunological studies is undoubtedly drawing us closer to that goal.</p></sec></body><back><sec sec-type="data-availability"><title>Data Availability</title><p>The data used to support the findings of this study are included within the article. Additional data are available from the corresponding author upon request.</p></sec><sec sec-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare that there are no conflicts of interest regarding the publication of this paper.</p></sec><ref-list><ref id="B1" content-type="article"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hargrave</surname><given-names>A.</given-names></name><name name-style="western"><surname>Salim Mustafa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hanif</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tunio</surname><given-names>J. H.</given-names></name><name name-style="western"><surname>Hanif</surname><given-names>S. N. M.</given-names></name></person-group><article-title>Current status of HIV-1 vaccines</article-title><source><italic toggle="yes">Vaccines</italic></source><year>2021</year><volume>9</volume><issue>9</issue><pub-id pub-id-type="doi">10.3390/vaccines9091026</pub-id><pub-id pub-id-type="publisher-id">1026</pub-id><pub-id pub-id-type="pmcid">PMC8471857</pub-id><pub-id pub-id-type="pmid">34579263</pub-id></element-citation></ref><ref id="B2" content-type="article"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pitisuttithum</surname><given-names>P.</given-names></name><name name-style="western"><surname>Marovich</surname><given-names>M. A.</given-names></name></person-group><article-title>Prophylactic HIV vaccine: vaccine regimens in clinical trials and potential challenges</article-title><source><italic toggle="yes">Expert Review of Vaccines</italic></source><year>2020</year><volume>19</volume><issue>2</issue><fpage>133</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1080/14760584.2020.1718497</pub-id><pub-id pub-id-type="pmid">31951766</pub-id></element-citation></ref><ref id="B3" content-type="misc"><label>3</label><element-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Hargrave</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mustafa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hanif</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tunio</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nida</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hanif</surname><given-names>M.</given-names></name></person-group><article-title>Immune response to HIV-1 infection and vaccine development</article-title><year>2023</year><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.intechopen.com" ext-link-type="uri">https://www.intechopen.com</ext-link></comment></element-citation></ref><ref id="B4" content-type="article"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>L. D.</given-names></name><name name-style="western"><surname>Moody</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>A. B.</given-names></name></person-group><article-title>Innovations in HIV-1 vaccine design</article-title><source><italic toggle="yes">Clinical Therapeutics</italic></source><year>2020</year><volume>42</volume><issue>3</issue><fpage>499</fpage><lpage>514</lpage><pub-id pub-id-type="doi">10.1016/j.clinthera.2020.01.009</pub-id><pub-id pub-id-type="pmid">32035643</pub-id><pub-id pub-id-type="pmcid">PMC7102617</pub-id></element-citation></ref><ref id="B5" content-type="article"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Korber</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gaschen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Yusim</surname><given-names>K.</given-names></name><name name-style="western"><surname>Thakallapally</surname><given-names>R.</given-names></name><name name-style="western"><surname>Detours</surname><given-names>V.</given-names></name></person-group><article-title>Evolutionary and immunological implications of contemporary HIV-1 variation</article-title><source><italic toggle="yes">British Medical Bulletin</italic></source><year>2001</year><volume>58</volume><issue>1</issue><fpage>19</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1093/bmb/58.1.19</pub-id><pub-id pub-id-type="other">2-s2.0-0035162494</pub-id><pub-id pub-id-type="pmid">11714622</pub-id></element-citation></ref><ref id="B6" content-type="article"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abram</surname><given-names>M. E.</given-names></name><name name-style="western"><surname>Ferris</surname><given-names>A. L.</given-names></name><name name-style="western"><surname>Shao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Alvord</surname><given-names>W. G.</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>S. H.</given-names></name></person-group><article-title>Nature, position, and frequency of mutations made in a single cycle of HIV-1 replication</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2010</year><volume>84</volume><issue>19</issue><fpage>9864</fpage><lpage>9878</lpage><pub-id pub-id-type="doi">10.1128/jvi.00915-10</pub-id><pub-id pub-id-type="other">2-s2.0-77956820495</pub-id><pub-id pub-id-type="pmid">20660205</pub-id><pub-id pub-id-type="pmcid">PMC2937799</pub-id></element-citation></ref><ref id="B7" content-type="article"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>W. S.</given-names></name><name name-style="western"><surname>Temin</surname><given-names>H. M.</given-names></name></person-group><article-title>Retroviral recombination and reverse transcription.</article-title><source><italic toggle="yes">Science</italic></source><year>1990</year><volume>250</volume><issue>4985</issue><fpage>1227</fpage><lpage>1233</lpage><pub-id pub-id-type="doi">10.1126/science.1700865</pub-id><pub-id pub-id-type="other">2-s2.0-0025635705</pub-id><pub-id pub-id-type="pmid">1700865</pub-id></element-citation></ref><ref id="B8" content-type="article"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Pomerantz</surname><given-names>R. J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Arunachalam</surname><given-names>S. C.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>L.</given-names></name></person-group><article-title>The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA</article-title><source><italic toggle="yes">Nature</italic></source><year>2003</year><volume>3</volume><issue>6944</issue><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature01707</pub-id><pub-id pub-id-type="pmcid">PMC1350966</pub-id><pub-id pub-id-type="pmid">12808465</pub-id></element-citation></ref><ref id="B9" content-type="article"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nora</surname><given-names>T.</given-names></name><name name-style="western"><surname>Charpentier</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tenaillon</surname><given-names>O.</given-names></name><name name-style="western"><surname>Hoede</surname><given-names>C.</given-names></name><name name-style="western"><surname>Clavel</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hance</surname><given-names>A. J.</given-names></name></person-group><article-title>Contribution of recombination to the evolution of human immunodeficiency viruses expressing resistance to antiretroviral treatment</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2007</year><volume>81</volume><issue>14</issue><fpage>7620</fpage><lpage>7628</lpage><pub-id pub-id-type="doi">10.1128/JVI.00083-07</pub-id><pub-id pub-id-type="other">2-s2.0-34447249033</pub-id><pub-id pub-id-type="pmid">17494080</pub-id><pub-id pub-id-type="pmcid">PMC1933369</pub-id></element-citation></ref><ref id="B10" content-type="article"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Plantier</surname><given-names>J.-C.</given-names></name><name name-style="western"><surname>Leoz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dickerson</surname><given-names>J. E.</given-names></name><etal/></person-group><article-title>A new human immunodeficiency virus derived from gorillas</article-title><source><italic toggle="yes">Nature Medicine</italic></source><year>2009</year><volume>15</volume><issue>8</issue><fpage>871</fpage><lpage>872</lpage><pub-id pub-id-type="doi">10.1038/nm.2016</pub-id><pub-id pub-id-type="other">2-s2.0-68349125395</pub-id><pub-id pub-id-type="pmid">19648927</pub-id></element-citation></ref><ref id="B11" content-type="article"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robertson</surname><given-names>D. L.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>J. P.</given-names></name><name name-style="western"><surname>Bradac</surname><given-names>J. A.</given-names></name><etal/></person-group><article-title>HIV-1 nomenclature proposal</article-title><source><italic toggle="yes">Science</italic></source><year>2000</year><volume>288</volume><issue>5463</issue><pub-id pub-id-type="doi">10.1126/science.288.5463.55d</pub-id><pub-id pub-id-type="publisher-id">55</pub-id><pub-id pub-id-type="pmid">10766634</pub-id></element-citation></ref><ref id="B12" content-type="article"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perrin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kaiser</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yerly</surname><given-names>S.</given-names></name></person-group><article-title>Travel and the spread of HIV-1 genetic variants</article-title><source><italic toggle="yes">The Lancet Infectious Diseases</italic></source><year>2003</year><volume>3</volume><issue>1</issue><fpage>22</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(03)00484-5</pub-id><pub-id pub-id-type="other">2-s2.0-0037221414</pub-id><pub-id pub-id-type="pmid">12505029</pub-id></element-citation></ref><ref id="B13" content-type="article"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shankarappa</surname><given-names>R.</given-names></name><name name-style="western"><surname>Margolick</surname><given-names>J. B.</given-names></name><name name-style="western"><surname>Gange</surname><given-names>S. J.</given-names></name><etal/></person-group><article-title>Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>1999</year><volume>73</volume><issue>12</issue><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/jvi.73.12.10489-10502.1999</pub-id><pub-id pub-id-type="pmcid">PMC113104</pub-id><pub-id pub-id-type="pmid">10559367</pub-id></element-citation></ref><ref id="B14" content-type="article"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Curlin</surname><given-names>M. E.</given-names></name><name name-style="western"><surname>Zioni</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hawes</surname><given-names>S. E.</given-names></name><etal/></person-group><article-title>Hiv-1 envelope subregion length variation during disease progression</article-title><source><italic toggle="yes">PLoS Pathogens</italic></source><year>2010</year><volume>6</volume><issue>12</issue><pub-id pub-id-type="doi">10.1371/journal.ppat.1001228</pub-id><pub-id pub-id-type="other">2-s2.0-78651237643</pub-id><pub-id pub-id-type="publisher-id">e1001228</pub-id><pub-id pub-id-type="pmcid">PMC3002983</pub-id><pub-id pub-id-type="pmid">21187897</pub-id></element-citation></ref><ref id="B15" content-type="article"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Checkley</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Luttge</surname><given-names>B. G.</given-names></name><name name-style="western"><surname>Freed</surname><given-names>E. O.</given-names></name></person-group><article-title>HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation</article-title><source><italic toggle="yes">Journal of Molecular Biology</italic></source><year>2011</year><volume>410</volume><issue>4</issue><fpage>582</fpage><lpage>608</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2011.04.042</pub-id><pub-id pub-id-type="other">2-s2.0-80051737642</pub-id><pub-id pub-id-type="pmid">21762802</pub-id><pub-id pub-id-type="pmcid">PMC3139147</pub-id></element-citation></ref><ref id="B16" content-type="article"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Diedrich</surname><given-names>J. K.</given-names></name><name name-style="western"><surname>Kulp</surname><given-names>D. W.</given-names></name><etal/></person-group><article-title>Global site-specific N-glycosylation analysis of HIV envelope glycoprotein</article-title><source><italic toggle="yes">Nature Communications</italic></source><year>2017</year><volume>8</volume><issue>1</issue><pub-id pub-id-type="doi">10.1038/ncomms14954</pub-id><pub-id pub-id-type="other">2-s2.0-85016232433</pub-id><pub-id pub-id-type="pmcid">PMC5379070</pub-id><pub-id pub-id-type="pmid">28348411</pub-id></element-citation></ref><ref id="B17" content-type="article"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bess</surname><given-names>J.</given-names><suffix>Jr</suffix></name><etal/></person-group><article-title>Distribution and three-dimensional structure of AIDS virus envelope spikes</article-title><source><italic toggle="yes">Nature</italic></source><year>2006</year><volume>441</volume><issue>7095</issue><fpage>847</fpage><lpage>852</lpage><pub-id pub-id-type="doi">10.1038/nature04817</pub-id><pub-id pub-id-type="other">2-s2.0-33745203490</pub-id><pub-id pub-id-type="pmid">16728975</pub-id></element-citation></ref><ref id="B18" content-type="article"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Finzi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sodroski</surname><given-names>J.</given-names></name></person-group><article-title>The conformational states of the HIV-1 envelope glycoproteins</article-title><source><italic toggle="yes">Trends in Microbiology</italic></source><year>2020</year><volume>28</volume><issue>8</issue><fpage>655</fpage><lpage>667</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2020.03.007</pub-id><pub-id pub-id-type="pmid">32418859</pub-id><pub-id pub-id-type="pmcid">PMC7363548</pub-id></element-citation></ref><ref id="B19" content-type="article"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>LaCasse</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Follis</surname><given-names>K. E.</given-names></name><name name-style="western"><surname>Trahey</surname><given-names>M.</given-names></name><name name-style="western"><surname>Scarborough</surname><given-names>J. D.</given-names></name><name name-style="western"><surname>Littman</surname><given-names>D. R.</given-names></name><name name-style="western"><surname>Nunberg</surname><given-names>J. H.</given-names></name></person-group><article-title>Fusion-competent vaccines: broad neutralization of primary isolates of HIV</article-title><source><italic toggle="yes">Science</italic></source><year>1999</year><volume>283</volume><issue>5400</issue><fpage>357</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1126/science.283.5400.357</pub-id><pub-id pub-id-type="other">2-s2.0-0033555453</pub-id><pub-id pub-id-type="pmid">9888845</pub-id></element-citation></ref><ref id="B20" content-type="article"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nunberg</surname><given-names>J. H.</given-names></name></person-group><article-title>Retraction</article-title><source><italic toggle="yes">Science</italic></source><year>2002</year><volume>296</volume><issue>5570</issue><fpage>1025</fpage><lpage>1025</lpage><pub-id pub-id-type="doi">10.1126/science.296.5570.1025b</pub-id><pub-id pub-id-type="pmid">12004901</pub-id></element-citation></ref><ref id="B21" content-type="misc"><label>21</label><element-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Lai</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>T.</given-names></name></person-group><article-title>Remune. Immune response</article-title><year>2022</year><fpage>391</fpage><lpage>398</lpage><pub-id pub-id-type="pmid">12054085</pub-id></element-citation></ref><ref id="B22" content-type="article"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fern&#225;ndez-Cruz</surname><given-names>E.</given-names></name><name name-style="western"><surname>Navarro</surname><given-names>J. D.</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Sainz</surname><given-names>C.</given-names></name><etal/></person-group><article-title>The potential role of the HIV-1 immunogen (Remune&#174;) as a therapeutic vaccine in the treatment of HIV infection</article-title><source><italic toggle="yes">Expert Review of Vaccines</italic></source><year>2014</year><volume>2</volume><issue>6</issue><fpage>739</fpage><lpage>752</lpage><pub-id pub-id-type="doi">10.1586/14760584.2.6.739</pub-id><pub-id pub-id-type="other">2-s2.0-0346849716</pub-id><pub-id pub-id-type="pmid">14711358</pub-id></element-citation></ref><ref id="B23" content-type="misc"><label>23</label><element-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>King</surname><given-names>S. R.</given-names></name></person-group><article-title>HIV: virology and mechanisms of disease</article-title><year>1992</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0196-0644(94)70181-4</pub-id><pub-id pub-id-type="pmid">7915889</pub-id></element-citation></ref><ref id="B24" content-type="article"><label>24</label><element-citation publication-type="journal"><collab>German Advisory Committee Blood (Arbeitskreis Blut), Subgroup &#8216;Assessment of Pathogens Transmissible by Blood&#8217;</collab><article-title>Human immunodeficiency virus (HIV)</article-title><source><italic toggle="yes">Transfusion Medicine and Hemotherapy</italic></source><year>2016</year><volume>43</volume><issue>3</issue><fpage>203</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1159/000445852</pub-id><pub-id pub-id-type="other">2-s2.0-84973487311</pub-id><pub-id pub-id-type="pmid">27403093</pub-id><pub-id pub-id-type="pmcid">PMC4924471</pub-id></element-citation></ref><ref id="B25" content-type="misc"><label>25</label><element-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Votteler</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schubert</surname><given-names>U.</given-names></name></person-group><article-title>Human immunodeficiency viruses: molecular biology</article-title><year>2008</year></element-citation></ref><ref id="B26" content-type="misc"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arrildt</surname><given-names>K. T.</given-names></name><name name-style="western"><surname>Joseph</surname><given-names>S. B.</given-names></name><name name-style="western"><surname>Swanstrom</surname><given-names>R.</given-names></name></person-group><article-title>The HIV-1 Env protein: a coat of many colors</article-title><source><italic toggle="yes">Current HIV/AIDS Reports</italic></source><year>2012</year><volume>9</volume><issue>1</issue><fpage>52</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1007/s11904-011-0107-3</pub-id><pub-id pub-id-type="other">2-s2.0-84858974464</pub-id><pub-id pub-id-type="pmid">22237899</pub-id><pub-id pub-id-type="pmcid">PMC3658113</pub-id></element-citation></ref><ref id="B27" content-type="article"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fasae</surname><given-names>M. B.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>Y.</given-names></name></person-group><article-title>The role of HIV Tat protein in HIV-related cardiovascular diseases</article-title><source><italic toggle="yes">Journal of Translational Medicine</italic></source><year>2018</year><volume>16</volume><issue>1</issue><pub-id pub-id-type="doi">10.1186/s12967-018-1500-0</pub-id><pub-id pub-id-type="other">2-s2.0-85046655958</pub-id><pub-id pub-id-type="pmcid">PMC5941636</pub-id><pub-id pub-id-type="pmid">29739413</pub-id></element-citation></ref><ref id="B28" content-type="article"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Izumi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Borbet</surname><given-names>T. C.</given-names></name><name name-style="western"><surname>Hagedorn</surname><given-names>A. N.</given-names></name><name name-style="western"><surname>Pathak</surname><given-names>V. K.</given-names></name></person-group><article-title>HIV-1 and HIV-2 Vif interact with human APOBEC3 proteins using completely different determinants</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2014</year><volume>88</volume><issue>17</issue><fpage>9893</fpage><lpage>9908</lpage><pub-id pub-id-type="doi">10.1128/jvi.01318-14</pub-id><pub-id pub-id-type="other">2-s2.0-84921980261</pub-id><pub-id pub-id-type="pmid">24942576</pub-id><pub-id pub-id-type="pmcid">PMC4136346</pub-id></element-citation></ref><ref id="B29" content-type="article"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muthumani</surname><given-names>K.</given-names></name><name name-style="western"><surname>Choo</surname><given-names>A. Y.</given-names></name><name name-style="western"><surname>Zong</surname><given-names>W. X.</given-names></name><etal/></person-group><article-title>The HIV-1 Vpr and glucocorticoid receptor complex is a gain-of-function interaction that prevents the nuclear localization of PARP-1</article-title><source><italic toggle="yes">Nature Cell Biology</italic></source><year>2006</year><volume>8</volume><issue>2</issue><fpage>170</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1038/ncb1352</pub-id><pub-id pub-id-type="other">2-s2.0-33645147708</pub-id><pub-id pub-id-type="pmid">16429131</pub-id><pub-id pub-id-type="pmcid">PMC3142937</pub-id></element-citation></ref><ref id="B30" content-type="article"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Estrabaud</surname><given-names>E.</given-names></name><name name-style="western"><surname>Le Rouzic</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lopez-Verg&#232;s</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Regulated degradation of the HIV-1 Vpu protein through a <italic toggle="yes">&#946;</italic>TrCP-independent pathway limits the release of viral particles</article-title><source><italic toggle="yes">PLoS Pathogens</italic></source><year>2007</year><volume>3</volume><issue>7</issue><fpage>995</fpage><lpage>1004</lpage><pub-id pub-id-type="doi">10.1371/journal.ppat.0030104</pub-id><pub-id pub-id-type="other">2-s2.0-34547628246</pub-id><pub-id pub-id-type="pmcid">PMC1933454</pub-id><pub-id pub-id-type="pmid">17676996</pub-id></element-citation></ref><ref id="B31" content-type="article"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>C. Y.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y.</given-names></name></person-group><article-title>Killed whole-HIV vaccine, employing a well established strategy for antiviral vaccines</article-title><source><italic toggle="yes">AIDS Research and Therapy</italic></source><year>2017</year><volume>14</volume><issue>1</issue><pub-id pub-id-type="doi">10.1186/s12981-017-0176-5</pub-id><pub-id pub-id-type="other">2-s2.0-85029217082</pub-id><pub-id pub-id-type="pmcid">PMC5594480</pub-id><pub-id pub-id-type="pmid">28893272</pub-id></element-citation></ref><ref id="B32" content-type="article"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Michalski</surname><given-names>C. J.</given-names></name><name name-style="western"><surname>Choo</surname><given-names>S. H.</given-names></name><etal/></person-group><article-title>First phase I human clinical trial of a killed whole-HIV-1 vaccine: demonstration of its safety and enhancement of anti-HIV antibody responses</article-title><source><italic toggle="yes">Retrovirology</italic></source><year>2016</year><volume>13</volume><issue>1</issue><pub-id pub-id-type="doi">10.1186/s12977-016-0317-2</pub-id><pub-id pub-id-type="other">2-s2.0-84999188102</pub-id><pub-id pub-id-type="pmcid">PMC5126836</pub-id><pub-id pub-id-type="pmid">27894306</pub-id></element-citation></ref><ref id="B33" content-type="article"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kirchhoff</surname><given-names>F.</given-names></name><name name-style="western"><surname>Geenough</surname><given-names>T. C.</given-names></name><name name-style="western"><surname>Brettler</surname><given-names>D. B.</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Desrosiers</surname><given-names>R. C.</given-names></name></person-group><article-title>Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection</article-title><source><italic toggle="yes">The New England Journal of Medicine</italic></source><year>1995</year><volume>332</volume><issue>4</issue><fpage>228</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1056/NEJM199501263320405</pub-id><pub-id pub-id-type="other">2-s2.0-0028835788</pub-id><pub-id pub-id-type="pmid">7808489</pub-id></element-citation></ref><ref id="B34" content-type="article"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Escolano</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dosenovic</surname><given-names>P.</given-names></name><name name-style="western"><surname>Nussenzweig</surname><given-names>M. C.</given-names></name></person-group><article-title>Progress toward active or passive HIV-1 vaccination</article-title><source><italic toggle="yes">Journal of Experimental Medicine</italic></source><year>2017</year><volume>214</volume><fpage>3</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1084/jem.20161765</pub-id><pub-id pub-id-type="other">2-s2.0-85008440477</pub-id><pub-id pub-id-type="pmid">28003309</pub-id><pub-id pub-id-type="pmcid">PMC5206506</pub-id></element-citation></ref><ref id="B35" content-type="article"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dolin</surname><given-names>R.</given-names></name><name name-style="western"><surname>Graham</surname><given-names>B. S.</given-names></name><name name-style="western"><surname>Greenberg</surname><given-names>S. B.</given-names></name><etal/></person-group><article-title>The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gpl60 candidate vaccine in humans</article-title><source><italic toggle="yes">Annals of Internal Medicine</italic></source><year>1991</year><volume>114</volume><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/0003-4819-114-2-119</pub-id><pub-id pub-id-type="pmid">1984386</pub-id></element-citation></ref><ref id="B36" content-type="article"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wright</surname><given-names>P. F.</given-names></name><name name-style="western"><surname>Lambert</surname><given-names>J. S.</given-names></name><name name-style="western"><surname>Gorse</surname><given-names>G. J.</given-names></name><etal/></person-group><article-title>Immunization with envelope MN rgp120 vaccine in human immunodeficiency virus-infected pregnant women</article-title><source><italic toggle="yes">The Journal of Infectious Disease</italic></source><year>1999</year><volume>180</volume><issue>4</issue><fpage>1080</fpage><lpage>1088</lpage><pub-id pub-id-type="doi">10.1086/314985</pub-id><pub-id pub-id-type="other">2-s2.0-0033370525</pub-id><pub-id pub-id-type="pmid">10479134</pub-id></element-citation></ref><ref id="B37" content-type="article"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Belshe</surname><given-names>R. B.</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gorse</surname><given-names>G. J.</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus type 1 vaccine with or without gp120: a phase 2 study in higher-and lower-risk volunteers</article-title><source><italic toggle="yes">The Journal of Infectious Diseases</italic></source><year>2001</year><volume>183</volume><issue>9</issue><fpage>1343</fpage><lpage>1352</lpage><pub-id pub-id-type="doi">10.1086/319863</pub-id><pub-id pub-id-type="other">2-s2.0-0035341521</pub-id><pub-id pub-id-type="pmid">11294665</pub-id></element-citation></ref><ref id="B38" content-type="article"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caputo</surname><given-names>V.</given-names></name><name name-style="western"><surname>Libera</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sisti</surname><given-names>S.</given-names></name><name name-style="western"><surname>Giuliani</surname><given-names>B.</given-names></name><name name-style="western"><surname>Diotti</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Criscuolo</surname><given-names>E.</given-names></name></person-group><article-title>The initial interplay between HIV and mucosal innate immunity</article-title><source><italic toggle="yes">Frontiers in Immunology</italic></source><year>2023</year><volume>14</volume><pub-id pub-id-type="doi">10.3389/fimmu.2023.1104423</pub-id><pub-id pub-id-type="publisher-id">e1104423</pub-id><pub-id pub-id-type="pmcid">PMC9927018</pub-id><pub-id pub-id-type="pmid">36798134</pub-id></element-citation></ref><ref id="B39" content-type="article"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Montefiori</surname><given-names>D. C.</given-names></name><name name-style="western"><surname>Roederer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>L.</given-names></name><name name-style="western"><surname>Seaman</surname><given-names>M. S.</given-names></name></person-group><article-title>Neutralization tiers of HIV-1</article-title><source><italic toggle="yes">Current Opinion in HIV and AIDS</italic></source><year>2018</year><volume>13</volume><issue>2</issue><fpage>128</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1097/COH.0000000000000442</pub-id><pub-id pub-id-type="other">2-s2.0-85042398847</pub-id><pub-id pub-id-type="pmid">29266013</pub-id><pub-id pub-id-type="pmcid">PMC5802254</pub-id></element-citation></ref><ref id="B40" content-type="article"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klasse</surname><given-names>P. J.</given-names></name><name name-style="western"><surname>Depetris</surname><given-names>R. S.</given-names></name><name name-style="western"><surname>Pejchal</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Influences on trimerization and aggregation of soluble, cleaved HIV-1 SOSIP envelope glycoprotein</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2013</year><volume>87</volume><issue>17</issue><fpage>9873</fpage><lpage>9885</lpage><pub-id pub-id-type="doi">10.1128/JVI.01226-13</pub-id><pub-id pub-id-type="other">2-s2.0-84883308389</pub-id><pub-id pub-id-type="pmid">23824824</pub-id><pub-id pub-id-type="pmcid">PMC3754145</pub-id></element-citation></ref><ref id="B41" content-type="article"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sch&#252;lke</surname><given-names>N.</given-names></name><name name-style="western"><surname>Vesanen</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Sanders</surname><given-names>R. W.</given-names></name><etal/></person-group><article-title>Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2002</year><volume>76</volume><issue>15</issue><fpage>7760</fpage><lpage>7776</lpage><pub-id pub-id-type="doi">10.1128/JVI.76.15.7760-7776.2002</pub-id><pub-id pub-id-type="other">2-s2.0-0036315133</pub-id><pub-id pub-id-type="pmid">12097589</pub-id><pub-id pub-id-type="pmcid">PMC136400</pub-id></element-citation></ref><ref id="B42" content-type="article"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanders</surname><given-names>R. W.</given-names></name><name name-style="western"><surname>Vesanen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schuelke</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2002</year><volume>76</volume><issue>17</issue><fpage>8875</fpage><lpage>8889</lpage><pub-id pub-id-type="doi">10.1128/JVI.76.17.8875-8889.2002</pub-id><pub-id pub-id-type="other">2-s2.0-0036333661</pub-id><pub-id pub-id-type="pmid">12163607</pub-id><pub-id pub-id-type="pmcid">PMC136973</pub-id></element-citation></ref><ref id="B43" content-type="article"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Das</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>S.</given-names></name><name name-style="western"><surname>Parray</surname><given-names>H. A.</given-names></name><name name-style="western"><surname>Samal</surname><given-names>S.</given-names></name></person-group><article-title>Efficiently cleaved HIV-1 envelopes: can they be important for vaccine immunogen development?</article-title><source><italic toggle="yes">Therapeutic Advances in Vaccines and Immunotherapy</italic></source><year>2020</year><volume>8</volume><pub-id pub-id-type="doi">10.1177/2515135520957763</pub-id><pub-id pub-id-type="pmcid">PMC7549152</pub-id><pub-id pub-id-type="pmid">33103053</pub-id></element-citation></ref><ref id="B44" content-type="article"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pauthner</surname><given-names>M.</given-names></name><name name-style="western"><surname>Havenar-Daughton</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sok</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Elicitation of robust tier 2 neutralizing antibody responses in nonhuman primates by HIV envelope trimer immunization using optimized approaches</article-title><source><italic toggle="yes">Immunity</italic></source><year>2017</year><volume>46</volume><issue>6</issue><fpage>1073</fpage><lpage>1088.e6</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2017.05.007</pub-id><pub-id pub-id-type="other">2-s2.0-85025101545</pub-id><pub-id pub-id-type="pmid">28636956</pub-id><pub-id pub-id-type="pmcid">PMC5483234</pub-id></element-citation></ref><ref id="B45" content-type="misc"><label>45</label><element-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Duggan</surname><given-names>N. N.</given-names></name><name name-style="western"><surname>Weisgrau</surname><given-names>K. L.</given-names></name><name name-style="western"><surname>Magnani</surname><given-names>D. M.</given-names></name><name name-style="western"><surname>Rakasz</surname><given-names>E. G.</given-names></name><name name-style="western"><surname>Desrosiers</surname><given-names>R. C.</given-names></name><name name-style="western"><surname>Martinez-Navio</surname><given-names>J. M.</given-names></name></person-group><article-title>SOSIP trimer-specific antibodies isolated from a simian-human immunodeficiency virus-infected monkey with versus without a pre-blocking step with gp41</article-title><year>2022</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.01582-21</pub-id><pub-id pub-id-type="pmcid">PMC8791287</pub-id><pub-id pub-id-type="pmid">34730398</pub-id></element-citation></ref><ref id="B46" content-type="article"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>S. K.</given-names></name><name name-style="western"><surname>deVal</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bale</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Cleavage-independent HIV-1 Env trimers engineered as soluble native spike mimetics for vaccine design</article-title><source><italic toggle="yes">Cell Reports</italic></source><year>2015</year><volume>11</volume><issue>4</issue><fpage>539</fpage><lpage>550</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2015.03.047</pub-id><pub-id pub-id-type="other">2-s2.0-84928583366</pub-id><pub-id pub-id-type="pmid">25892233</pub-id><pub-id pub-id-type="pmcid">PMC4637274</pub-id></element-citation></ref><ref id="B47" content-type="article"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lewis</surname><given-names>G. K.</given-names></name></person-group><article-title>Challenges of antibody-mediated protection against HIV-1</article-title><source><italic toggle="yes">Expert Review of Vaccines</italic></source><year>2010</year><volume>9</volume><issue>7</issue><fpage>683</fpage><lpage>687</lpage><pub-id pub-id-type="doi">10.1586/erv.10.70</pub-id><pub-id pub-id-type="other">2-s2.0-77954662179</pub-id><pub-id pub-id-type="pmid">20624038</pub-id><pub-id pub-id-type="pmcid">PMC4104498</pub-id></element-citation></ref><ref id="B48" content-type="article"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wright</surname><given-names>P. F.</given-names></name><name name-style="western"><surname>Mestecky</surname><given-names>J.</given-names></name><name name-style="western"><surname>Juliana McElrath</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein</article-title><source><italic toggle="yes">The Journal of Infectious Disease</italic></source><year>2004</year><volume>189</volume><issue>7</issue><fpage>1221</fpage><lpage>1231</lpage><pub-id pub-id-type="doi">10.1086/382088</pub-id><pub-id pub-id-type="other">2-s2.0-11144356581</pub-id><pub-id pub-id-type="pmid">15031791</pub-id></element-citation></ref><ref id="B49" content-type="article"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daly</surname><given-names>L. M.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>P. A.</given-names></name><name name-style="western"><surname>Donnelly</surname><given-names>G.</given-names></name><name name-style="western"><surname>Nicolson</surname><given-names>C.</given-names></name><name name-style="western"><surname>Robertson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mills</surname><given-names>K. H. G.</given-names></name></person-group><article-title>Innate IL-10 promotes the induction of Th2 responses with plasmid DNA expressing HIV gp120</article-title><source><italic toggle="yes">Vaccine</italic></source><year>2005</year><volume>23</volume><issue>7</issue><fpage>963</fpage><lpage>974</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2004.03.072</pub-id><pub-id pub-id-type="other">2-s2.0-10444240255</pub-id><pub-id pub-id-type="pmid">15603899</pub-id></element-citation></ref><ref id="B50" content-type="article"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>N. P. Y.</given-names></name><name name-style="western"><surname>Matthews</surname><given-names>K.</given-names></name><name name-style="western"><surname>Klasse</surname><given-names>P. J.</given-names></name><name name-style="western"><surname>Sanders</surname><given-names>R. W.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>J. P.</given-names></name></person-group><article-title>HIV-1 gp120 impairs the induction of B cell responses by TLR9-activated plasmacytoid dendritic cells</article-title><source><italic toggle="yes">The Journal of Immunology</italic></source><year>2012</year><volume>189</volume><issue>11</issue><fpage>5257</fpage><lpage>5265</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1201905</pub-id><pub-id pub-id-type="other">2-s2.0-84869795022</pub-id><pub-id pub-id-type="pmid">23100517</pub-id><pub-id pub-id-type="pmcid">PMC3504132</pub-id></element-citation></ref><ref id="B51" content-type="article"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klasse</surname><given-names>P. J.</given-names></name><name name-style="western"><surname>Ozorowski</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sanders</surname><given-names>R. W.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>J. P.</given-names></name></person-group><article-title>Env exceptionalism: why are HIV-1 Env glycoproteins atypical immunogens?</article-title><source><italic toggle="yes">Cell Host and Microbe</italic></source><year>2020</year><volume>27</volume><issue>4</issue><fpage>507</fpage><lpage>518</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2020.03.018</pub-id><pub-id pub-id-type="pmid">32272076</pub-id><pub-id pub-id-type="pmcid">PMC7187920</pub-id></element-citation></ref><ref id="B52" content-type="article"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mikell</surname><given-names>I.</given-names></name><name name-style="western"><surname>Sather</surname><given-names>D. N.</given-names></name><name name-style="western"><surname>Kalams</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Altfeld</surname><given-names>M.</given-names></name><name name-style="western"><surname>Alter</surname><given-names>G.</given-names></name><name name-style="western"><surname>Stamatatos</surname><given-names>L.</given-names></name></person-group><article-title>Characteristics of the earliest cross-neutralizing antibody response to HIV-1</article-title><source><italic toggle="yes">PLoS Pathogens</italic></source><year>2011</year><volume>7</volume><issue>1</issue><pub-id pub-id-type="doi">10.1371/journal.ppat.1001251</pub-id><pub-id pub-id-type="other">2-s2.0-79551518897</pub-id><pub-id pub-id-type="pmcid">PMC3020924</pub-id><pub-id pub-id-type="pmid">21249232</pub-id></element-citation></ref><ref id="B53" content-type="article"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haynes</surname><given-names>B. F.</given-names></name><name name-style="western"><surname>Wiehe</surname><given-names>K.</given-names></name><name name-style="western"><surname>Borrow</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies</article-title><source><italic toggle="yes">Nature Reviews Immunology</italic></source><year>2023</year><volume>23</volume><fpage>142</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1038/s41577-022-00753-w</pub-id><pub-id pub-id-type="pmcid">PMC9372928</pub-id><pub-id pub-id-type="pmid">35962033</pub-id></element-citation></ref><ref id="B54" content-type="article"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daniels</surname><given-names>C. N.</given-names></name><name name-style="western"><surname>Saunders</surname><given-names>K. O.</given-names></name></person-group><article-title>Antibody responses to the HIV-1 envelope high mannose patch</article-title><source><italic toggle="yes">Advances in Immunology</italic></source><year>2019</year><volume>143</volume><fpage>11</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1016/bs.ai.2019.08.002</pub-id><pub-id pub-id-type="other">2-s2.0-85071977833</pub-id><pub-id pub-id-type="pmid">31607367</pub-id><pub-id pub-id-type="pmcid">PMC7480283</pub-id></element-citation></ref><ref id="B55" content-type="article"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing</article-title><source><italic toggle="yes">Science</italic></source><year>2011</year><volume>333</volume><issue>6049</issue><fpage>1593</fpage><lpage>1602</lpage><pub-id pub-id-type="doi">10.1126/science.1207532</pub-id><pub-id pub-id-type="other">2-s2.0-80052942203</pub-id><pub-id pub-id-type="pmid">21835983</pub-id><pub-id pub-id-type="pmcid">PMC3516815</pub-id></element-citation></ref><ref id="B56" content-type="article"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barbas Iii</surname><given-names>C. F.</given-names></name><name name-style="western"><surname>Bjorlingt</surname><given-names>E.</given-names></name><name name-style="western"><surname>Chiodit</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro</article-title><source><italic toggle="yes">Proceedings of the National Academy of Sciences</italic></source><year>1992</year><volume>89</volume><issue>19</issue><fpage>9339</fpage><lpage>9343</lpage><pub-id pub-id-type="doi">10.1073/pnas.89.19.9339</pub-id><pub-id pub-id-type="other">2-s2.0-0026655937</pub-id><pub-id pub-id-type="pmcid">PMC50122</pub-id><pub-id pub-id-type="pmid">1384050</pub-id></element-citation></ref><ref id="B57" content-type="article"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z.-Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1</article-title><source><italic toggle="yes">Science</italic></source><year>2010</year><volume>329</volume><issue>5993</issue><fpage>856</fpage><lpage>861</lpage><pub-id pub-id-type="doi">10.1126/science.1187659</pub-id><pub-id pub-id-type="other">2-s2.0-77954920017</pub-id><pub-id pub-id-type="pmid">20616233</pub-id><pub-id pub-id-type="pmcid">PMC2965066</pub-id></element-citation></ref><ref id="B58" content-type="article"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trkola</surname><given-names>A.</given-names></name><name name-style="western"><surname>Purtscher</surname><given-names>M.</given-names></name><name name-style="western"><surname>Muster</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>1996</year><volume>70</volume><issue>2</issue><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/jvi.70.2.1100-1108.1996</pub-id><pub-id pub-id-type="pmcid">PMC189917</pub-id><pub-id pub-id-type="pmid">8551569</pub-id></element-citation></ref><ref id="B59" content-type="article"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ofek</surname><given-names>G.</given-names></name><name name-style="western"><surname>Laub</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Broad and potent neutralization of HIV-1 by a gp41-specific human antibody</article-title><source><italic toggle="yes">Nature</italic></source><year>2012</year><volume>491</volume><issue>7424</issue><fpage>406</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1038/nature11544</pub-id><pub-id pub-id-type="other">2-s2.0-84866493348</pub-id><pub-id pub-id-type="pmid">23151583</pub-id><pub-id pub-id-type="pmcid">PMC4854285</pub-id></element-citation></ref><ref id="B60" content-type="misc"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zwick</surname><given-names>M. B.</given-names></name><name name-style="western"><surname>Labrijn</surname><given-names>A. F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41</article-title><source><italic toggle="yes">Journal of Virology</italic></source><year>2001</year><volume>75</volume><issue>22</issue><fpage>10892</fpage><lpage>10905</lpage><pub-id pub-id-type="doi">10.1128/jvi.75.22.10892-10905.2001</pub-id><pub-id pub-id-type="other">2-s2.0-0034759882</pub-id><pub-id pub-id-type="pmid">11602729</pub-id><pub-id pub-id-type="pmcid">PMC114669</pub-id></element-citation></ref><ref id="B61" content-type="article"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corti</surname><given-names>D.</given-names></name><name name-style="western"><surname>Langedijk</surname><given-names>J. P. M.</given-names></name><name name-style="western"><surname>Hinz</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals</article-title><source><italic toggle="yes">PLoS ONE</italic></source><year>2010</year><volume>5</volume><issue>1</issue><pub-id pub-id-type="doi">10.1371/journal.pone.0008805</pub-id><pub-id pub-id-type="other">2-s2.0-77649318846</pub-id><pub-id pub-id-type="pmcid">PMC2808385</pub-id><pub-id pub-id-type="pmid">20098712</pub-id></element-citation></ref><ref id="B62" content-type="article"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pantophlet</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dennis</surname><given-names>R. B.</given-names></name></person-group><article-title>Immunofocusing: antigen engineering to promote the induction of HIV-neutralizing antibodies</article-title><source><italic toggle="yes">Trends in Molecular Medicine</italic></source><year>2003</year><volume>9</volume><issue>11</issue><fpage>468</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.1016/j.molmed.2003.09.001</pub-id><pub-id pub-id-type="other">2-s2.0-0344009558</pub-id><pub-id pub-id-type="pmid">14604823</pub-id></element-citation></ref><ref id="B63" content-type="article"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haynes</surname><given-names>B. F.</given-names></name><name name-style="western"><surname>Fleming</surname><given-names>J.</given-names></name><name name-style="western"><surname>St. Clair</surname><given-names>E. W.</given-names></name><etal/></person-group><article-title>Immunology: cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies</article-title><source><italic toggle="yes">Science</italic></source><year>2005</year><volume>308</volume><issue>5730</issue><fpage>1906</fpage><lpage>1908</lpage><pub-id pub-id-type="doi">10.1126/science.1111781</pub-id><pub-id pub-id-type="other">2-s2.0-21344434534</pub-id><pub-id pub-id-type="pmid">15860590</pub-id></element-citation></ref><ref id="B64" content-type="article"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wiehe</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bradley</surname><given-names>T.</given-names></name><name name-style="western"><surname>Meyerhoff</surname><given-names>R. R.</given-names></name><etal/></person-group><article-title>Functional relevance of improbable antibody mutations for HIV broadly neutralizing antibody development</article-title><source><italic toggle="yes">Cell Host and Microbe</italic></source><year>2018</year><volume>23</volume><issue>6</issue><fpage>759</fpage><lpage>765.e6</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2018.04.018</pub-id><pub-id pub-id-type="other">2-s2.0-85047425490</pub-id><pub-id pub-id-type="pmid">29861171</pub-id><pub-id pub-id-type="pmcid">PMC6002614</pub-id></element-citation></ref><ref id="B65" content-type="article"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>West</surname><given-names>A. P.</given-names></name><name name-style="western"><surname>Scharf</surname><given-names>L.</given-names></name><name name-style="western"><surname>Scheid</surname><given-names>J. F.</given-names></name><name name-style="western"><surname>Klein</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bjorkman</surname><given-names>P. J.</given-names></name><name name-style="western"><surname>Nussenzweig</surname><given-names>M. C.</given-names></name></person-group><article-title>Structural insights on the role of antibodies in HIV-1 vaccine and therapy</article-title><source><italic toggle="yes">Cell</italic></source><year>2014</year><volume>156</volume><issue>4</issue><fpage>633</fpage><lpage>648</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.01.052</pub-id><pub-id pub-id-type="other">2-s2.0-84894173514</pub-id><pub-id pub-id-type="pmid">24529371</pub-id><pub-id pub-id-type="pmcid">PMC4041625</pub-id></element-citation></ref><ref id="B66" content-type="article"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scheid</surname><given-names>J. F.</given-names></name><name name-style="western"><surname>Mouquet</surname><given-names>H.</given-names></name><name name-style="western"><surname>Feldhahn</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals</article-title><source><italic toggle="yes">Nature</italic></source><year>2009</year><volume>458</volume><issue>7238</issue><fpage>636</fpage><lpage>640</lpage><pub-id pub-id-type="doi">10.1038/nature07930</pub-id><pub-id pub-id-type="other">2-s2.0-63849131879</pub-id><pub-id pub-id-type="pmid">19287373</pub-id></element-citation></ref><ref id="B67" content-type="article"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klein</surname><given-names>F.</given-names></name><name name-style="western"><surname>Diskin</surname><given-names>R.</given-names></name><name name-style="western"><surname>Scheid</surname><given-names>J. F.</given-names></name><etal/></person-group><article-title>Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization</article-title><source><italic toggle="yes">Cell</italic></source><year>2013</year><volume>153</volume><issue>1</issue><fpage>126</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.03.018</pub-id><pub-id pub-id-type="other">2-s2.0-84875759341</pub-id><pub-id pub-id-type="pmid">23540694</pub-id><pub-id pub-id-type="pmcid">PMC3792590</pub-id></element-citation></ref><ref id="B68" content-type="article"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scheid</surname><given-names>J. F.</given-names></name><name name-style="western"><surname>Mouquet</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ueberheide</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Sequence and structural convergence of broad and potent hiv antibodies that mimic CD4 binding</article-title><source><italic toggle="yes">Science</italic></source><year>2011</year><volume>333</volume><issue>6049</issue><fpage>1633</fpage><lpage>1637</lpage><pub-id pub-id-type="doi">10.1126/science.1207227</pub-id><pub-id pub-id-type="other">2-s2.0-80052925616</pub-id><pub-id pub-id-type="pmid">21764753</pub-id><pub-id pub-id-type="pmcid">PMC3351836</pub-id></element-citation></ref><ref id="B69" content-type="article"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens</article-title><source><italic toggle="yes">Biochemical and Biophysical Research Communications</italic></source><year>2009</year><volume>390</volume><issue>3</issue><fpage>404</fpage><lpage>409</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2009.09.029</pub-id><pub-id pub-id-type="other">2-s2.0-70449701456</pub-id><pub-id pub-id-type="pmid">19748484</pub-id><pub-id pub-id-type="pmcid">PMC2787893</pub-id></element-citation></ref><ref id="B70" content-type="article"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Breden</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lepik</surname><given-names>C.</given-names></name><name name-style="western"><surname>Longo</surname><given-names>N. S.</given-names></name><name name-style="western"><surname>Montero</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lipsky</surname><given-names>P. E.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>J. K.</given-names></name></person-group><article-title>Comparison of antibody repertoires produced by HIV-1 infection, other chronic and acute infections, and systemic autoimmune disease</article-title><source><italic toggle="yes">PLoS ONE</italic></source><year>2011</year><volume>6</volume><issue>3</issue><pub-id pub-id-type="doi">10.1371/journal.pone.0016857</pub-id><pub-id pub-id-type="other">2-s2.0-79953316880</pub-id><pub-id pub-id-type="pmcid">PMC3068138</pub-id><pub-id pub-id-type="pmid">21479208</pub-id></element-citation></ref><ref id="B71" content-type="misc"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jardine</surname><given-names>J. G.</given-names></name><name name-style="western"><surname>Ota</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sok</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen</article-title><source><italic toggle="yes">Science</italic></source><year>2015</year><volume>349</volume><issue>6244</issue><fpage>156</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1126/science.aac5894</pub-id><pub-id pub-id-type="other">2-s2.0-84934954773</pub-id><pub-id pub-id-type="pmid">26089355</pub-id><pub-id pub-id-type="pmcid">PMC4669217</pub-id></element-citation></ref><ref id="B72" content-type="article"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dosenovic</surname><given-names>P.</given-names></name><name name-style="western"><surname>von Boehmer</surname><given-names>L.</given-names></name><name name-style="western"><surname>Escolano</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Immunization for HIV-1 broadly neutralizing antibodies in human Ig knockin mice</article-title><source><italic toggle="yes">Cell</italic></source><year>2015</year><volume>161</volume><issue>7</issue><fpage>1505</fpage><lpage>1515</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.06.003</pub-id><pub-id pub-id-type="other">2-s2.0-84934937791</pub-id><pub-id pub-id-type="pmid">26091035</pub-id><pub-id pub-id-type="pmcid">PMC4604566</pub-id></element-citation></ref><ref id="B73" content-type="article"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kwong</surname><given-names>P. D.</given-names></name><name name-style="western"><surname>Mascola</surname><given-names>J. R.</given-names></name></person-group><article-title>HIV-1 vaccines based on antibody identification, B cell ontogeny, and epitope structure</article-title><source><italic toggle="yes">Immunity</italic></source><year>2018</year><volume>48</volume><issue>5</issue><fpage>855</fpage><lpage>871</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2018.04.029</pub-id><pub-id pub-id-type="other">2-s2.0-85046663340</pub-id><pub-id pub-id-type="pmid">29768174</pub-id></element-citation></ref><ref id="B74" content-type="article"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Doria-Rose</surname><given-names>N. A.</given-names></name><name name-style="western"><surname>Schramm</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>Gorman</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies</article-title><source><italic toggle="yes">Nature</italic></source><year>2014</year><volume>508</volume><issue>7498</issue><fpage>55</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1038/nature13036</pub-id><pub-id pub-id-type="other">2-s2.0-84899991983</pub-id><pub-id pub-id-type="pmid">24590074</pub-id><pub-id pub-id-type="pmcid">PMC4395007</pub-id></element-citation></ref><ref id="B75" content-type="article"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liao</surname><given-names>H.-X.</given-names></name><name name-style="western"><surname>Lynch</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus</article-title><source><italic toggle="yes">Nature</italic></source><year>2013</year><volume>496</volume><fpage>469</fpage><lpage>476</lpage><pub-id pub-id-type="doi">10.1038/nature12053</pub-id><pub-id pub-id-type="other">2-s2.0-84876797103</pub-id><pub-id pub-id-type="pmid">23552890</pub-id><pub-id pub-id-type="pmcid">PMC3637846</pub-id></element-citation></ref><ref id="B76" content-type="article"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>MacLeod</surname><given-names>D. T.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>N. M.</given-names></name><name name-style="western"><surname>Briney</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Early antibody lineage diversification and independent limb maturation lead to broad HIV-1 neutralization targeting the env high-mannose patch</article-title><source><italic toggle="yes">Immunity</italic></source><year>2016</year><volume>44</volume><issue>5</issue><fpage>1215</fpage><lpage>1226</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2016.04.016</pub-id><pub-id pub-id-type="other">2-s2.0-84967148279</pub-id><pub-id pub-id-type="pmid">27192579</pub-id><pub-id pub-id-type="pmcid">PMC5003182</pub-id></element-citation></ref><ref id="B77" content-type="article"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jardine</surname><given-names>J. G.</given-names></name><name name-style="western"><surname>Kulp</surname><given-names>D. W.</given-names></name><name name-style="western"><surname>Havenar-Daughton</surname><given-names>C.</given-names></name><etal/></person-group><article-title>HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen</article-title><source><italic toggle="yes">Science</italic></source><year>2016</year><volume>351</volume><issue>6280</issue><fpage>1458</fpage><lpage>1463</lpage><pub-id pub-id-type="doi">10.1126/science.aad9195</pub-id><pub-id pub-id-type="other">2-s2.0-84962251178</pub-id><pub-id pub-id-type="pmid">27013733</pub-id><pub-id pub-id-type="pmcid">PMC4872700</pub-id></element-citation></ref><ref id="B78" content-type="article"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>T.</given-names></name><name name-style="western"><surname>Georgiev</surname><given-names>I.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01</article-title><source><italic toggle="yes">Science</italic></source><year>2010</year><volume>329</volume><issue>5993</issue><fpage>811</fpage><lpage>817</lpage><pub-id pub-id-type="doi">10.1126/science.1192819</pub-id><pub-id pub-id-type="other">2-s2.0-77954943648</pub-id><pub-id pub-id-type="pmid">20616231</pub-id><pub-id pub-id-type="pmcid">PMC2981354</pub-id></element-citation></ref><ref id="B79" content-type="article"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>B. H.</given-names></name><name name-style="western"><surname>Ishida</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Identification of a CD4-binding-site antibody to HIV that evolved near-pan neutralization breadth</article-title><source><italic toggle="yes">Immunity</italic></source><year>2016</year><volume>45</volume><issue>5</issue><fpage>1108</fpage><lpage>1121</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2016.10.027</pub-id><pub-id pub-id-type="other">2-s2.0-84999836139</pub-id><pub-id pub-id-type="pmid">27851912</pub-id><pub-id pub-id-type="pmcid">PMC5770152</pub-id></element-citation></ref><ref id="B80" content-type="article"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies</article-title><source><italic toggle="yes">Immunity</italic></source><year>2013</year><volume>39</volume><issue>2</issue><fpage>245</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2013.04.012</pub-id><pub-id pub-id-type="other">2-s2.0-84882589754</pub-id><pub-id pub-id-type="pmid">23911655</pub-id><pub-id pub-id-type="pmcid">PMC3985390</pub-id></element-citation></ref><ref id="B81" content-type="article"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>J. H.</given-names></name><name name-style="western"><surname>Toy</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kos</surname><given-names>J. T.</given-names></name><etal/></person-group><article-title>Vaccine genetics of IGHV1-2 VRC01-class broadly neutralizing antibody precursor na&#239;ve human B cells</article-title><source><italic toggle="yes">Npj Vaccines</italic></source><year>2021</year><volume>6</volume><pub-id pub-id-type="doi">10.1038/s41541-021-00376-7</pub-id><pub-id pub-id-type="publisher-id">113</pub-id><pub-id pub-id-type="pmcid">PMC8421370</pub-id><pub-id pub-id-type="pmid">34489473</pub-id></element-citation></ref><ref id="B82" content-type="article"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McGuire</surname><given-names>A. T.</given-names></name><name name-style="western"><surname>Gray</surname><given-names>M. D.</given-names></name><name name-style="western"><surname>Dosenovic</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice</article-title><source><italic toggle="yes">Nature Communications</italic></source><year>2016</year><volume>7</volume><pub-id pub-id-type="doi">10.1038/ncomms10618</pub-id><pub-id pub-id-type="other">2-s2.0-84959378678</pub-id><pub-id pub-id-type="pmcid">PMC4770077</pub-id><pub-id pub-id-type="pmid">26907590</pub-id></element-citation></ref><ref id="B83" content-type="article"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Medina-Ram&#237;rez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Garces</surname><given-names>F.</given-names></name><name name-style="western"><surname>Escolano</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo</article-title><source><italic toggle="yes">Journal of Experimental Medicine</italic></source><year>2017</year><volume>214</volume><issue>9</issue><fpage>2573</fpage><lpage>2590</lpage><pub-id pub-id-type="doi">10.1084/jem.20161160</pub-id><pub-id pub-id-type="other">2-s2.0-85028886518</pub-id><pub-id pub-id-type="pmid">28847869</pub-id><pub-id pub-id-type="pmcid">PMC5584115</pub-id></element-citation></ref><ref id="B84" content-type="article"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caniels</surname><given-names>T. G.</given-names></name><name name-style="western"><surname>Medina-Ram&#237;rez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Germline-targeting HIV-1 Env vaccination induces VRC01-class antibodies with rare insertions</article-title><source><italic toggle="yes">Cell Reports Medicine</italic></source><year>2023</year><volume>4</volume><issue>4</issue><pub-id pub-id-type="doi">10.1016/j.xcrm.2023.101003</pub-id><pub-id pub-id-type="pmcid">PMC10140475</pub-id><pub-id pub-id-type="pmid">37044090</pub-id></element-citation></ref><ref id="B85" content-type="article"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tian</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Induction of HIV neutralizing antibody lineages in mice with diverse precursor repertoires</article-title><source><italic toggle="yes">Cell</italic></source><year>2016</year><volume>166</volume><issue>6</issue><fpage>1471</fpage><lpage>1484.e18</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.07.029</pub-id><pub-id pub-id-type="other">2-s2.0-84986300672</pub-id><pub-id pub-id-type="pmid">27610571</pub-id><pub-id pub-id-type="pmcid">PMC5103708</pub-id></element-citation></ref><ref id="B86" content-type="article"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ota</surname><given-names>T.</given-names></name><name name-style="western"><surname>Doyle-Cooper</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>A. B.</given-names></name><etal/></person-group><article-title>B cells from knock-in mice expressing broadly neutralizing HIV antibody b12 carry an innocuous B cell receptor responsive to HIV vaccine candidates</article-title><source><italic toggle="yes">The Journal of Immunology</italic></source><year>2013</year><volume>191</volume><issue>6</issue><fpage>3179</fpage><lpage>3185</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1301283</pub-id><pub-id pub-id-type="other">2-s2.0-84884262472</pub-id><pub-id pub-id-type="pmid">23940273</pub-id><pub-id pub-id-type="pmcid">PMC3773231</pub-id></element-citation></ref><ref id="B87" content-type="article"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>Y. R.</given-names></name><name name-style="western"><surname>Parks</surname><given-names>K. R.</given-names></name><name name-style="western"><surname>Weidle</surname><given-names>C.</given-names></name><etal/></person-group><article-title>HIV-1 VRC01 germline-targeting immunogens select distinct epitope-specific B cell receptors</article-title><source><italic toggle="yes">Immunity</italic></source><year>2020</year><volume>53</volume><issue>4</issue><fpage>840</fpage><lpage>851.e6</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2020.09.007</pub-id><pub-id pub-id-type="pmid">33053332</pub-id><pub-id pub-id-type="pmcid">PMC7735217</pub-id></element-citation></ref><ref id="B88" content-type="article"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Abbott</surname><given-names>R. K.</given-names></name><name name-style="western"><surname>Havenar-Daughton</surname><given-names>C.</given-names></name><etal/></person-group><article-title>B cells expressing authentic naive human VRC01-class BCRs can be recruited to germinal centers and affinity mature in multiple independent mouse models</article-title><source><italic toggle="yes">Proceedings of the National Academy of Sciences</italic></source><year>2020</year><volume>117</volume><issue>37</issue><fpage>22920</fpage><lpage>22931</lpage><pub-id pub-id-type="doi">10.1073/pnas.2004489117</pub-id><pub-id pub-id-type="pmcid">PMC7502816</pub-id><pub-id pub-id-type="pmid">32873644</pub-id></element-citation></ref><ref id="B89" content-type="article"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kepler</surname><given-names>T. B.</given-names></name><name name-style="western"><surname>Wiehe</surname><given-names>K.</given-names></name></person-group><article-title>Genetic and structural analyses of affinity maturation in the humoral response to HIV-1</article-title><source><italic toggle="yes">Immunological Reviews</italic></source><year>2017</year><volume>275</volume><fpage>129</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1111/imr.12513</pub-id><pub-id pub-id-type="other">2-s2.0-85010877307</pub-id><pub-id pub-id-type="pmid">28133793</pub-id><pub-id pub-id-type="pmcid">PMC5362126</pub-id></element-citation></ref><ref id="B90" content-type="misc"><label>90</label><element-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Wiehe</surname><given-names>K.</given-names></name><name name-style="western"><surname>Saunders</surname><given-names>K. O.</given-names></name><name name-style="western"><surname>Stalls</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Mutation-guided vaccine design: a strategy for developing boosting immunogens for HIV broadly neutralizing antibody induction</article-title><year>2022</year><pub-id pub-id-type="doi">10.1101/2022.11.11.516143</pub-id><pub-id pub-id-type="pmid">38670093</pub-id></element-citation></ref><ref id="B91" content-type="article"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kwong</surname><given-names>P. D.</given-names></name></person-group><article-title>What are the most powerful immunogen design vaccine strategies? A structural biologist&#8217;s perspective</article-title><source><italic toggle="yes">Cold Spring Harbor Perspectives in Biology</italic></source><year>2017</year><volume>9</volume><issue>11</issue><pub-id pub-id-type="doi">10.1101/cshperspect.a029470</pub-id><pub-id pub-id-type="other">2-s2.0-85032990442</pub-id><pub-id pub-id-type="pmcid">PMC5666634</pub-id><pub-id pub-id-type="pmid">28159876</pub-id></element-citation></ref><ref id="B92" content-type="article"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kong</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J. H.</given-names></name><name name-style="western"><surname>Doores</surname><given-names>K. J.</given-names></name><etal/></person-group><article-title>Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120</article-title><source><italic toggle="yes">Nature Structural and Molecular Biology</italic></source><year>2013</year><volume>20</volume><issue>7</issue><fpage>796</fpage><lpage>803</lpage><pub-id pub-id-type="doi">10.1038/nsmb.2594</pub-id><pub-id pub-id-type="other">2-s2.0-84880161438</pub-id><pub-id pub-id-type="pmcid">PMC3823233</pub-id><pub-id pub-id-type="pmid">23708606</pub-id></element-citation></ref><ref id="B93" content-type="article"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sok</surname><given-names>D.</given-names></name><name name-style="western"><surname>Laserson</surname><given-names>U.</given-names></name><name name-style="western"><surname>Laserson</surname><given-names>J.</given-names></name><etal/></person-group><article-title>The effects of somatic hypermutation on neutralization and binding in the pgt121 family of broadly neutralizing HIV antibodies</article-title><source><italic toggle="yes">PLoS Pathogens</italic></source><year>2013</year><volume>9</volume><issue>11</issue><pub-id pub-id-type="doi">10.1371/journal.ppat.1003754</pub-id><pub-id pub-id-type="other">2-s2.0-84888251984</pub-id><pub-id pub-id-type="publisher-id">e1003754</pub-id><pub-id pub-id-type="pmcid">PMC3836729</pub-id><pub-id pub-id-type="pmid">24278016</pub-id></element-citation></ref><ref id="B94" content-type="article"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garces</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sok</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Structural evolution of glycan recognition by a family of potent HIV antibodies</article-title><source><italic toggle="yes">Cell</italic></source><year>2014</year><volume>159</volume><issue>1</issue><fpage>69</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.09.009</pub-id><pub-id pub-id-type="other">2-s2.0-84907527916</pub-id><pub-id pub-id-type="pmid">25259921</pub-id><pub-id pub-id-type="pmcid">PMC4278586</pub-id></element-citation></ref><ref id="B95" content-type="article"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steichen</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Kulp</surname><given-names>D. W.</given-names></name><name name-style="western"><surname>Tokatlian</surname><given-names>T.</given-names></name><etal/></person-group><article-title>HIV vaccine design to target germline precursors of glycan-dependent broadly neutralizing antibodies</article-title><source><italic toggle="yes">Immunity</italic></source><year>2016</year><volume>45</volume><issue>3</issue><fpage>483</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2016.08.016</pub-id><pub-id pub-id-type="other">2-s2.0-84990876450</pub-id><pub-id pub-id-type="pmid">27617678</pub-id><pub-id pub-id-type="pmcid">PMC5040827</pub-id></element-citation></ref><ref id="B96" content-type="article"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Escolano</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gristick</surname><given-names>H. B.</given-names></name><name name-style="western"><surname>Gautam</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Sequential immunization of macaques elicits heterologous neutralizing antibodies targeting the V3-glycan patch of HIV-1 Env</article-title><source><italic toggle="yes">Science Translational Medicine</italic></source><year>2021</year><volume>13</volume><issue>621</issue><pub-id pub-id-type="doi">10.1126/scitranslmed.abk1533</pub-id><pub-id pub-id-type="pmcid">PMC8932345</pub-id><pub-id pub-id-type="pmid">34818054</pub-id></element-citation></ref><ref id="B97" content-type="article"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Escolano</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gristick</surname><given-names>H. B.</given-names></name><name name-style="western"><surname>Abernathy</surname><given-names>M. E.</given-names></name><etal/></person-group><article-title>Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques</article-title><source><italic toggle="yes">Nature</italic></source><year>2019</year><volume>570</volume><issue>7762</issue><fpage>468</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1250-z</pub-id><pub-id pub-id-type="other">2-s2.0-85066803291</pub-id><pub-id pub-id-type="pmid">31142836</pub-id><pub-id pub-id-type="pmcid">PMC6657810</pub-id></element-citation></ref><ref id="B98" content-type="article"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jerne</surname><given-names>N. K.</given-names></name></person-group><article-title>Towards a network theory of the immune system</article-title><source><italic toggle="yes">Annales d&#8217;Immunologie</italic></source><year>1974</year><volume>125</volume><fpage>373</fpage><lpage>389</lpage><pub-id pub-id-type="pmid">4142565</pub-id></element-citation></ref><ref id="B99" content-type="article"><label>99</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morrow</surname><given-names>W.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>T.</given-names></name><name name-style="western"><surname>Haigwood</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Anti-idiotypic antisera raised against monoclonal antibody specific for a p24 gag region epitope detects a common interspecies idiotype associated with anti-HIV responses</article-title><source><italic toggle="yes">Viral Immunology</italic></source><year>1990</year><volume>3</volume><issue>2</issue><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/vim.1990.3.99</pub-id><pub-id pub-id-type="pmid">1694432</pub-id></element-citation></ref><ref id="B100" content-type="article"><label>100</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ni</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dzakah</surname><given-names>E. E.</given-names></name><etal/></person-group><article-title>Development of monoclonal antibodies against HIV-1 p24 protein and its application in colloidal gold immunochromatographic assay for HIV-1 detection</article-title><source><italic toggle="yes">BioMed Research International</italic></source><year>2016</year><volume>2016</volume><fpage>6</fpage><pub-id pub-id-type="doi">10.1155/2016/6743904</pub-id><pub-id pub-id-type="other">2-s2.0-84962911031</pub-id><pub-id pub-id-type="publisher-id">6743904</pub-id><pub-id pub-id-type="pmcid">PMC4812187</pub-id><pub-id pub-id-type="pmid">27069923</pub-id></element-citation></ref><ref id="B101" content-type="article"><label>101</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hohmann</surname><given-names>A.</given-names></name><name name-style="western"><surname>Peters</surname><given-names>V.</given-names></name><name name-style="western"><surname>Comacchio</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bradley</surname><given-names>J.</given-names></name></person-group><article-title>Mouse monoclonal anti-idiotypic antibodies to HIV p24: immunochemical properties and internal imagery</article-title><source><italic toggle="yes">Molecular Immunology</italic></source><year>1993</year><volume>30</volume><issue>6</issue><fpage>521</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1016/0161-5890(93)90026-8</pub-id><pub-id pub-id-type="other">2-s2.0-0027516588</pub-id><pub-id pub-id-type="pmid">8487775</pub-id></element-citation></ref><ref id="B102" content-type="article"><label>102</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corre</surname><given-names>J.-P.</given-names></name><name name-style="western"><surname>Fevrier</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chamaret</surname><given-names>S.</given-names></name><name name-style="western"><surname>Thkze</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zouali</surname><given-names>M.</given-names></name></person-group><article-title>Anti-idiotypic antibodies to human anti-gp120 antibodies bind recombinant and cellular human CD4</article-title><source><italic toggle="yes">European Journal of Immunology</italic></source><year>1991</year><volume>21</volume><issue>3</issue><fpage>743</fpage><lpage>751</lpage><pub-id pub-id-type="doi">10.1002/eji.1830210330</pub-id><pub-id pub-id-type="other">2-s2.0-0025972715</pub-id><pub-id pub-id-type="pmid">1672646</pub-id></element-citation></ref><ref id="B103" content-type="article"><label>103</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>C.-Y.</given-names></name><name name-style="western"><surname>Narat</surname><given-names>P.</given-names></name><name name-style="western"><surname>Chamat</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Anti-idiotype monoclonal antibody elicits broadly neutralizing anti-gpl20 antibodies in monkeys</article-title><source><italic toggle="yes">Proceedings of the National Academy of Sciences</italic></source><year>1992</year><volume>89</volume><issue>7</issue><fpage>2546</fpage><lpage>2550</lpage><pub-id pub-id-type="doi">10.1073/pnas.89.7.2546</pub-id><pub-id pub-id-type="other">2-s2.0-0026576916</pub-id><pub-id pub-id-type="pmcid">PMC48698</pub-id><pub-id pub-id-type="pmid">1557358</pub-id></element-citation></ref><ref id="B104" content-type="article"><label>104</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burioni</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mancini</surname><given-names>N.</given-names></name><name name-style="western"><surname>De Marco</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Anti-HIV-1 response elicited in rabbits by anti-idiotype monoclonal antibodies mimicking the CD4-binding site</article-title><source><italic toggle="yes">PLoS ONE</italic></source><year>2008</year><volume>3</volume><issue>10</issue><pub-id pub-id-type="doi">10.1371/journal.pone.0003423</pub-id><pub-id pub-id-type="other">2-s2.0-54849437925</pub-id><pub-id pub-id-type="publisher-id">e3423</pub-id><pub-id pub-id-type="pmcid">PMC2565497</pub-id><pub-id pub-id-type="pmid">18923648</pub-id></element-citation></ref><ref id="B105" content-type="article"><label>105</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Praveen</surname><given-names>K.</given-names></name></person-group><article-title>Long term non-progressor (LTNP) HIV infection</article-title><source><italic toggle="yes">The Indian Journal of Medical Research</italic></source><year>2013</year><volume>138</volume><issue>3</issue><fpage>291</fpage><lpage>293</lpage><pub-id pub-id-type="pmid">24135172</pub-id><pub-id pub-id-type="pmcid">PMC3818590</pub-id></element-citation></ref><ref id="B106" content-type="article"><label>106</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muller</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Silverman</surname><given-names>G. J.</given-names></name><name name-style="western"><surname>Bramlet</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kohler</surname><given-names>H.</given-names></name></person-group><article-title>B-cell abnormalities in AIDS: stable and clonally-restricted antibody response in HIV-1 infection</article-title><source><italic toggle="yes">Scandinavian Journal of Immunology</italic></source><year>1993</year><volume>38</volume><issue>4</issue><fpage>327</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1111/j.1365-3083.1993.tb01734.x</pub-id><pub-id pub-id-type="other">2-s2.0-0027488833</pub-id><pub-id pub-id-type="pmid">7692591</pub-id></element-citation></ref><ref id="B107" content-type="article"><label>107</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Muller</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kohler</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zolla-Pazner</surname><given-names>S.</given-names></name></person-group><article-title>Human monoclonal and polyclonal anti-human immunodeficiency virus-1 antibodies share a common clonotypic specificity</article-title><source><italic toggle="yes">European Journal of Immunology</italic></source><year>1992</year><volume>22</volume><issue>7</issue><fpage>1749</fpage><lpage>1755</lpage><pub-id pub-id-type="doi">10.1002/eji.1830220713</pub-id><pub-id pub-id-type="other">2-s2.0-0026776364</pub-id><pub-id pub-id-type="pmid">1378015</pub-id></element-citation></ref><ref id="B108" content-type="article"><label>108</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Q. L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.-T.</given-names></name><name name-style="western"><surname>Blalock</surname><given-names>E.</given-names></name><name name-style="western"><surname>Muller</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kohler</surname><given-names>H.</given-names></name></person-group><article-title>Identification of an idiotypic peptide recognized by autoantibodies in human immunodeficiency Virus-1-infected individuals</article-title><source><italic toggle="yes">The Journal of Clinical Investigation</italic></source><year>1995</year><volume>96</volume><issue>2</issue><fpage>775</fpage><lpage>780</lpage><pub-id pub-id-type="doi">10.1172/JCI118122</pub-id><pub-id pub-id-type="other">2-s2.0-0029121921</pub-id><pub-id pub-id-type="pmid">7635971</pub-id><pub-id pub-id-type="pmcid">PMC185262</pub-id></element-citation></ref><ref id="B109" content-type="article"><label>109</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blalock</surname><given-names>J. E.</given-names></name></person-group><article-title>Complementarity of peptides specified by &#8217;sense&#8217; and &#8216;antisense&#8217; strands of DNA</article-title><source><italic toggle="yes">Trends in Biotechnology</italic></source><year>1990</year><volume>8</volume><fpage>140</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1016/0167-7799(90)90159-u</pub-id><pub-id pub-id-type="other">2-s2.0-0025347742</pub-id><pub-id pub-id-type="pmid">1369993</pub-id></element-citation></ref><ref id="B110" content-type="article"><label>110</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grant</surname><given-names>M.</given-names></name><name name-style="western"><surname>Smaill</surname><given-names>F.</given-names></name><name name-style="western"><surname>Muller</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kohler</surname><given-names>H.</given-names></name><name name-style="western"><surname>Rosenthal</surname><given-names>K.</given-names></name></person-group><article-title>The anti-idiotypic antibody 1F7 selectively inhibits cytotoxic T cells activated in HIV-1 infection</article-title><source><italic toggle="yes">Immunology and Cell Biology</italic></source><year>2000</year><volume>78</volume><issue>1</issue><fpage>20</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">10651925</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1440-1711.2000.00879.x</pub-id></element-citation></ref><ref id="B111" content-type="article"><label>111</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muller</surname><given-names>S.</given-names></name><name name-style="western"><surname>Parsons</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Kohler</surname><given-names>H.</given-names></name><name name-style="western"><surname>Grant</surname><given-names>M.</given-names></name></person-group><article-title>The significance of a common idiotype (1F7) on antibodies against human immune deficiency virus type 1 and hepatitis C virus</article-title><source><italic toggle="yes">Frontiers in Oncology</italic></source><year>2016</year><volume>6</volume><issue>Feb</issue><pub-id pub-id-type="doi">10.3389/fonc.2016.00011</pub-id><pub-id pub-id-type="other">2-s2.0-84964546154</pub-id><pub-id pub-id-type="pmcid">PMC4742788</pub-id><pub-id pub-id-type="pmid">26904499</pub-id></element-citation></ref><ref id="B112" content-type="article"><label>112</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dosenovic</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pettersson</surname><given-names>A. K.</given-names></name><name name-style="western"><surname>Wall</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Anti-idiotypic antibodies elicit anti-HIV-1-specific B cell responses</article-title><source><italic toggle="yes">Journal of Experimental Medicine</italic></source><year>2019</year><volume>216</volume><issue>10</issue><fpage>2316</fpage><lpage>2330</lpage><pub-id pub-id-type="doi">10.1084/jem.20190446</pub-id><pub-id pub-id-type="other">2-s2.0-85072985424</pub-id><pub-id pub-id-type="pmid">31345931</pub-id><pub-id pub-id-type="pmcid">PMC6780999</pub-id></element-citation></ref><ref id="B113" content-type="article"><label>113</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bancroft</surname><given-names>T.</given-names></name><name name-style="western"><surname>DeBuysscher</surname><given-names>B. L.</given-names></name><name name-style="western"><surname>Weidle</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Detection and activation of HIV broadly neutralizing antibody precursor B cells using anti-idiotypes</article-title><source><italic toggle="yes">Journal of Experimental Medicine</italic></source><year>2019</year><volume>216</volume><issue>10</issue><fpage>2331</fpage><lpage>2347</lpage><pub-id pub-id-type="doi">10.1084/jem.20190164</pub-id><pub-id pub-id-type="other">2-s2.0-85072994082</pub-id><pub-id pub-id-type="pmid">31345930</pub-id><pub-id pub-id-type="pmcid">PMC6780997</pub-id></element-citation></ref><ref id="B114" content-type="article"><label>114</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seydoux</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>Y.-H.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Development of a VRC01-class germline targeting immunogen derived from anti-idiotypic antibodies</article-title><source><italic toggle="yes">Cell Reports</italic></source><year>2021</year><volume>35</volume><issue>5</issue><pub-id pub-id-type="doi">10.1016/j.celrep.2021.109084</pub-id><pub-id pub-id-type="pmcid">PMC8127986</pub-id><pub-id pub-id-type="pmid">33951425</pub-id></element-citation></ref><ref id="B115" content-type="article"><label>115</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Groot</surname><given-names>A. S.</given-names></name><name name-style="western"><surname>Bishop</surname><given-names>E. A.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Engineering immunogenic consensus T helper epitopes for a cross-clade HIV vaccine</article-title><source><italic toggle="yes">Methods</italic></source><year>2004</year><volume>34</volume><issue>4</issue><fpage>476</fpage><lpage>487</lpage><pub-id pub-id-type="doi">10.1016/j.ymeth.2004.06.003</pub-id><pub-id pub-id-type="other">2-s2.0-7944235123</pub-id><pub-id pub-id-type="pmid">15542374</pub-id></element-citation></ref><ref id="B116" content-type="article"><label>116</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Groot</surname><given-names>A. S.</given-names></name><name name-style="western"><surname>Marcon</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bishop</surname><given-names>E. A.</given-names></name><etal/></person-group><article-title>HIV vaccine development by computer assisted design: the GAIA vaccine</article-title><source><italic toggle="yes">Vaccine</italic></source><year>2005</year><volume>23</volume><issue>17-18</issue><fpage>2136</fpage><lpage>2148</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2005.01.097</pub-id><pub-id pub-id-type="other">2-s2.0-14844302633</pub-id><pub-id pub-id-type="pmid">15755584</pub-id></element-citation></ref><ref id="B117" content-type="misc"><label>117</label><element-citation publication-type="other"><collab>EpiVax</collab><article-title>Pipeline</article-title><comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://epivax.com/pipeline" ext-link-type="uri">https://epivax.com/pipeline</ext-link></comment></element-citation></ref><ref id="B118" content-type="article"><label>118</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Naveed</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ali</surname><given-names>U.</given-names></name><name name-style="western"><surname>Aziz</surname><given-names>T.</given-names></name><etal/></person-group><article-title>A reverse vaccinology approach to design an mRNA-based vaccine to provoke a robust immune response against HIV-1</article-title><source><italic toggle="yes">Acta Biochimica Polonica</italic></source><year>2023</year><volume>70</volume><issue>2</issue><fpage>407</fpage><lpage>418</lpage><pub-id pub-id-type="doi">10.18388/abp.2020_6696</pub-id><pub-id pub-id-type="pmid">37329562</pub-id></element-citation></ref><ref id="B119" content-type="article"><label>119</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sette</surname><given-names>A.</given-names></name><name name-style="western"><surname>Livingston</surname><given-names>B.</given-names></name><name name-style="western"><surname>McKinney</surname><given-names>D.</given-names></name><etal/></person-group><article-title>The development of multi-epitope vaccines: epitope identification, vaccine design and clinical evaluation</article-title><source><italic toggle="yes">Biologicals</italic></source><year>2001</year><volume>29</volume><issue>3-4</issue><fpage>271</fpage><lpage>276</lpage><pub-id pub-id-type="doi">10.1006/biol.2001.0297</pub-id><pub-id pub-id-type="other">2-s2.0-0035697665</pub-id><pub-id pub-id-type="pmid">11851327</pub-id></element-citation></ref><ref id="B120" content-type="article"><label>120</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fonseca</surname><given-names>S. G.</given-names></name><name name-style="western"><surname>Coutinho-Silva</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fonseca</surname><given-names>A. M.</given-names></name><etal/></person-group><article-title>Identification of novel consensus CD4 T-cell epitopes from clade B HIV-1 whole genome that are frequently recognized by HIV-1 infected patients</article-title><source><italic toggle="yes">AIDS</italic></source><year>2006</year><volume>20</volume><issue>18</issue><fpage>2263</fpage><lpage>2273</lpage><pub-id pub-id-type="doi">10.1097/01.aids.0000253353.48331.5f</pub-id><pub-id pub-id-type="other">2-s2.0-33751242462</pub-id><pub-id pub-id-type="pmid">17117012</pub-id></element-citation></ref><ref id="B121" content-type="article"><label>121</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>M. A.</given-names></name></person-group><article-title>Immunologic basis of vaccine vectors</article-title><source><italic toggle="yes">Immunity</italic></source><year>2010</year><volume>33</volume><issue>4</issue><fpage>504</fpage><lpage>515</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2010.10.004</pub-id><pub-id pub-id-type="other">2-s2.0-77958469466</pub-id><pub-id pub-id-type="pmid">21029961</pub-id></element-citation></ref><ref id="B122" content-type="article"><label>122</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosa</surname><given-names>D. S.</given-names></name><name name-style="western"><surname>Ribeiro</surname><given-names>S. P.</given-names></name><name name-style="western"><surname>Almeida</surname><given-names>R. R.</given-names></name><etal/></person-group><article-title>A DNA vaccine encoding multiple HIV CD4 epitopes elicits vigorous polyfunctional, long-lived CD4+ and CD8+ T cell responses</article-title><source><italic toggle="yes">PLoS ONE</italic></source><year>2011</year><volume>6</volume><issue>2</issue><pub-id pub-id-type="doi">10.1371/journal.pone.0016921</pub-id><pub-id pub-id-type="other">2-s2.0-79951816846</pub-id><pub-id pub-id-type="publisher-id">e16921</pub-id><pub-id pub-id-type="pmcid">PMC3037933</pub-id><pub-id pub-id-type="pmid">21347287</pub-id></element-citation></ref><ref id="B123" content-type="article"><label>123</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ribeiro</surname><given-names>S. P.</given-names></name><name name-style="western"><surname>De Moura Mattaraia</surname><given-names>V. G.</given-names></name><name name-style="western"><surname>Almeida</surname><given-names>R. R.</given-names></name><etal/></person-group><article-title>A promiscuous T cell epitope-based HIV vaccine providing redundant population coverage of the HLA class II elicits broad, polyfunctional T cell responses in nonhuman primates</article-title><source><italic toggle="yes">Vaccine</italic></source><year>2022</year><volume>40</volume><issue>2</issue><fpage>239</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2021.11.076</pub-id><pub-id pub-id-type="pmid">34961636</pub-id></element-citation></ref><ref id="B124" content-type="article"><label>124</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases</article-title><source><italic toggle="yes">Signal Transduction and Targeted Therapy</italic></source><year>2023</year><volume>8</volume><issue>1</issue><pub-id pub-id-type="doi">10.1038/s41392-023-01408-5</pub-id><pub-id pub-id-type="pmcid">PMC10081433</pub-id><pub-id pub-id-type="pmid">37029123</pub-id></element-citation></ref><ref id="B125" content-type="article"><label>125</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gray</surname><given-names>G.</given-names></name><name name-style="western"><surname>Buchbinder</surname><given-names>S.</given-names></name><name name-style="western"><surname>Duerr</surname><given-names>A.</given-names></name></person-group><article-title>Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine</article-title><source><italic toggle="yes">Current Opinion in HIV and AIDS</italic></source><year>2010</year><volume>5</volume><issue>5</issue><fpage>357</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1097/COH.0b013e32833d2d2b</pub-id><pub-id pub-id-type="other">2-s2.0-77955513770</pub-id><pub-id pub-id-type="pmid">20978374</pub-id><pub-id pub-id-type="pmcid">PMC2995949</pub-id></element-citation></ref><ref id="B126" content-type="article"><label>126</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gray</surname><given-names>G. E.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Moodie</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study</article-title><source><italic toggle="yes">The Lancet Infectious Diseases</italic></source><year>2011</year><volume>11</volume><issue>7</issue><fpage>507</fpage><lpage>515</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(11)70098-6</pub-id><pub-id pub-id-type="other">2-s2.0-79959301474</pub-id><pub-id pub-id-type="pmid">21570355</pub-id><pub-id pub-id-type="pmcid">PMC3417349</pub-id></element-citation></ref><ref id="B127" content-type="article"><label>127</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baden</surname><given-names>L. R.</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>S. R.</given-names></name><name name-style="western"><surname>Seaman</surname><given-names>M. S.</given-names></name><etal/></person-group><article-title>First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001)</article-title><source><italic toggle="yes">The Journal of Infectious Diseases</italic></source><year>2013</year><volume>207</volume><issue>2</issue><fpage>240</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1093/infdis/jis670</pub-id><pub-id pub-id-type="other">2-s2.0-84871769381</pub-id><pub-id pub-id-type="pmid">23125444</pub-id><pub-id pub-id-type="pmcid">PMC3532831</pub-id></element-citation></ref><ref id="B128" content-type="article"><label>128</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hammer</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Sobieszczyk</surname><given-names>M. E.</given-names></name><name name-style="western"><surname>Janes</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine</article-title><source><italic toggle="yes">New England Journal of Medicine</italic></source><year>2013</year><volume>369</volume><issue>22</issue><fpage>2083</fpage><lpage>2092</lpage><pub-id pub-id-type="doi">10.1056/nejmoa1310566</pub-id><pub-id pub-id-type="other">2-s2.0-84887865083</pub-id><pub-id pub-id-type="pmid">24099601</pub-id><pub-id pub-id-type="pmcid">PMC4030634</pub-id></element-citation></ref><ref id="B129" content-type="article"><label>129</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Priddy</surname><given-names>F. H.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>D. J. M.</given-names></name><name name-style="western"><surname>Gelderblom</surname><given-names>H. C.</given-names></name><etal/></person-group><article-title>Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial</article-title><source><italic toggle="yes">The Lancet HIV</italic></source><year>2019</year><volume>6</volume><issue>4</issue><fpage>e230</fpage><lpage>e239</lpage><pub-id pub-id-type="doi">10.1016/S2352-3018(19)30003-7</pub-id><pub-id pub-id-type="other">2-s2.0-85063475855</pub-id><pub-id pub-id-type="pmid">30885692</pub-id><pub-id pub-id-type="pmcid">PMC6443625</pub-id></element-citation></ref><ref id="B130" content-type="article"><label>130</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pitisuttithum</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rerks-Ngarm</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bussaratid</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in Thailand</article-title><source><italic toggle="yes">PLoS ONE</italic></source><year>2011</year><volume>6</volume><issue>12</issue><pub-id pub-id-type="doi">10.1371/journal.pone.0027837</pub-id><pub-id pub-id-type="other">2-s2.0-83755174375</pub-id><pub-id pub-id-type="pmcid">PMC3244387</pub-id><pub-id pub-id-type="pmid">22205930</pub-id></element-citation></ref><ref id="B131" content-type="article"><label>131</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rerks-Ngarm</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pitisuttithum</surname><given-names>P.</given-names></name><name name-style="western"><surname>Excler</surname><given-names>J.-L.</given-names></name><etal/></person-group><article-title>Randomized, double-blind evaluation of late boost strategies for HIV-uninfected vaccine recipients in the RV144 HIV vaccine efficacy trial</article-title><source><italic toggle="yes">Journal of Infectious Diseases</italic></source><year>2017</year><volume>215</volume><issue>8</issue><fpage>1255</fpage><lpage>1263</lpage><pub-id pub-id-type="doi">10.1093/infdis/jix099</pub-id><pub-id pub-id-type="other">2-s2.0-85026694601</pub-id><pub-id pub-id-type="pmid">28329190</pub-id><pub-id pub-id-type="pmcid">PMC5853427</pub-id></element-citation></ref><ref id="B132" content-type="article"><label>132</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pantaleo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Janes</surname><given-names>H.</given-names></name><name name-style="western"><surname>Karuna</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial</article-title><source><italic toggle="yes">The Lancet HIV</italic></source><year>2019</year><volume>6</volume><issue>11</issue><fpage>e737</fpage><lpage>e749</lpage><pub-id pub-id-type="doi">10.1016/S2352-3018(19)30262-0</pub-id><pub-id pub-id-type="other">2-s2.0-85073978722</pub-id><pub-id pub-id-type="pmid">31601541</pub-id><pub-id pub-id-type="pmcid">PMC7156919</pub-id></element-citation></ref><ref id="B133" content-type="article"><label>133</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gray</surname><given-names>G. E.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Grunenberg</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa</article-title><source><italic toggle="yes">Science Translational Medicine</italic></source><year>2019</year><volume>11</volume><issue>510</issue><pub-id pub-id-type="doi">10.1126/scitranslmed.aax1880</pub-id><pub-id pub-id-type="other">2-s2.0-85072382216</pub-id><pub-id pub-id-type="pmcid">PMC7199879</pub-id><pub-id pub-id-type="pmid">31534016</pub-id></element-citation></ref><ref id="B134" content-type="article"><label>134</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pitisuttithum</surname><given-names>P.</given-names></name><name name-style="western"><surname>Nitayaphan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chariyalertsak</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial</article-title><source><italic toggle="yes">The Lancet HIV</italic></source><year>2020</year><volume>7</volume><issue>4</issue><fpage>e238</fpage><lpage>e248</lpage><pub-id pub-id-type="doi">10.1016/S2352-3018(19)30406-0</pub-id><pub-id pub-id-type="pmid">32035516</pub-id><pub-id pub-id-type="pmcid">PMC7247755</pub-id></element-citation></ref><ref id="B135" content-type="article"><label>135</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bekker</surname><given-names>L.-G.</given-names></name><name name-style="western"><surname>Moodie</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Grunenberg</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial</article-title><source><italic toggle="yes">The Lancet HIV</italic></source><year>2018</year><volume>5</volume><issue>7</issue><fpage>e366</fpage><lpage>e378</lpage><pub-id pub-id-type="doi">10.1016/S2352-3018(18)30071-7</pub-id><pub-id pub-id-type="other">2-s2.0-85048155729</pub-id><pub-id pub-id-type="pmid">29898870</pub-id><pub-id pub-id-type="pmcid">PMC6028742</pub-id></element-citation></ref><ref id="B136" content-type="article"><label>136</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gray</surname><given-names>G. E.</given-names></name><name name-style="western"><surname>Bekker</surname><given-names>L.-G.</given-names></name><name name-style="western"><surname>Laher</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Vaccine efficacy of ALVAC-HIV and bivalent subtype C gp120-MF59 in adults</article-title><source><italic toggle="yes">New England Journal of Medicine</italic></source><year>2021</year><volume>384</volume><issue>12</issue><fpage>1089</fpage><lpage>1100</lpage><pub-id pub-id-type="doi">10.1056/nejmoa2031499</pub-id><pub-id pub-id-type="pmid">33761206</pub-id><pub-id pub-id-type="pmcid">PMC7888373</pub-id></element-citation></ref><ref id="B137" content-type="article"><label>137</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leal</surname><given-names>L.</given-names></name><name name-style="western"><surname>Guardo</surname><given-names>A. C.</given-names></name><name name-style="western"><surname>Moron-Lopez</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Phase I clinical trial of an intranodally administered mRNA-based therapeutic vaccine against HIV-1 infection</article-title><source><italic toggle="yes">AIDS</italic></source><year>2018</year><volume>32</volume><issue>17</issue><fpage>2533</fpage><lpage>2545</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000002026</pub-id><pub-id pub-id-type="other">2-s2.0-85055806414</pub-id><pub-id pub-id-type="pmid">30289805</pub-id><pub-id pub-id-type="pmcid">PMC6221380</pub-id></element-citation></ref><ref id="B138" content-type="article"><label>138</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Jong</surname><given-names>W.</given-names></name><name name-style="western"><surname>Aerts</surname><given-names>J.</given-names></name><name name-style="western"><surname>Allard</surname><given-names>S.</given-names></name><etal/></person-group><article-title>iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy</article-title><source><italic toggle="yes">Trials</italic></source><year>2019</year><volume>20</volume><issue>1</issue><pub-id pub-id-type="doi">10.1186/s13063-019-3409-1</pub-id><pub-id pub-id-type="other">2-s2.0-85067398420</pub-id><pub-id pub-id-type="pmcid">PMC6580477</pub-id><pub-id pub-id-type="pmid">31208472</pub-id></element-citation></ref><ref id="B139" content-type="article"><label>139</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sallard</surname><given-names>E.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Aydin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schr&#246;er</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ehrhardt</surname><given-names>A.</given-names></name></person-group><article-title>The adenovirus vector platform: novel insights into rational vector design and lessons learned from the COVID-19 vaccine</article-title><source><italic toggle="yes">Viruses</italic></source><year>2023</year><volume>15</volume><issue>1</issue><pub-id pub-id-type="doi">10.3390/v15010204</pub-id><pub-id pub-id-type="pmcid">PMC9862123</pub-id><pub-id pub-id-type="pmid">36680244</pub-id></element-citation></ref><ref id="B140" content-type="article"><label>140</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Travieso</surname><given-names>T.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mahesh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mello</surname><given-names>J. D. F. R. E.</given-names></name><name name-style="western"><surname>Blasi</surname><given-names>M.</given-names></name></person-group><article-title>The use of viral vectors in vaccine development</article-title><source><italic toggle="yes">npj Vaccines</italic></source><year>2022</year><volume>7</volume><pub-id pub-id-type="doi">10.1038/s41541-022-00503-y</pub-id><pub-id pub-id-type="publisher-id">75</pub-id><pub-id pub-id-type="pmcid">PMC9253346</pub-id><pub-id pub-id-type="pmid">35787629</pub-id></element-citation></ref><ref id="B141" content-type="article"><label>141</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fischer</surname><given-names>W.</given-names></name><name name-style="western"><surname>Perkins</surname><given-names>S.</given-names></name><name name-style="western"><surname>Theiler</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants</article-title><source><italic toggle="yes">Nature Medicine</italic></source><year>2007</year><volume>13</volume><issue>1</issue><fpage>100</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1038/nm1461</pub-id><pub-id pub-id-type="other">2-s2.0-33846111016</pub-id><pub-id pub-id-type="pmid">17187074</pub-id></element-citation></ref><ref id="B142" content-type="article"><label>142</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barouch</surname><given-names>D. H.</given-names></name><name name-style="western"><surname>Alter</surname><given-names>G.</given-names></name><name name-style="western"><surname>Broge</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys</article-title><source><italic toggle="yes">Science</italic></source><year>2015</year><volume>349</volume><issue>6245</issue><fpage>316</fpage><lpage>320</lpage><pub-id pub-id-type="doi">10.1126/science.aab3886</pub-id><pub-id pub-id-type="other">2-s2.0-84937950533</pub-id><pub-id pub-id-type="pmid">26138104</pub-id><pub-id pub-id-type="pmcid">PMC4653134</pub-id></element-citation></ref><ref id="B143" content-type="article"><label>143</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zolla-Pazner</surname><given-names>S.</given-names></name><name name-style="western"><surname>Michael</surname><given-names>N. L.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J. H.</given-names></name></person-group><article-title>A tale of four studies: HIV vaccine immunogenicity and efficacy in clinical trials</article-title><source><italic toggle="yes">The Lancet HIV</italic></source><year>2021</year><volume>8</volume><fpage>e449</fpage><lpage>e452</lpage><pub-id pub-id-type="doi">10.1016/S2352-3018(21)00073-4</pub-id><pub-id pub-id-type="pmid">34029515</pub-id><pub-id pub-id-type="pmcid">PMC8449712</pub-id></element-citation></ref><ref id="B144" content-type="article"><label>144</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barouch</surname><given-names>D. H.</given-names></name><name name-style="western"><surname>Tomaka</surname><given-names>F. L.</given-names></name><name name-style="western"><surname>Wegmann</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)</article-title><source><italic toggle="yes">The Lancet</italic></source><year>2018</year><volume>392</volume><issue>10143</issue><fpage>232</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(18)31364-3</pub-id><pub-id pub-id-type="other">2-s2.0-85050038130</pub-id><pub-id pub-id-type="pmcid">PMC6192527</pub-id><pub-id pub-id-type="pmid">30047376</pub-id></element-citation></ref><ref id="B145" content-type="article"><label>145</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Vasan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J. H.</given-names></name><name name-style="western"><surname>Ake</surname><given-names>J. A.</given-names></name></person-group><article-title>Current approaches to HIV vaccine development: a narrative review</article-title><source><italic toggle="yes">Journal of the International AIDS Society</italic></source><year>2021</year><volume>2021</volume><issue>S7</issue><pub-id pub-id-type="doi">10.1002/jia2.25793</pub-id><pub-id pub-id-type="publisher-id">25793</pub-id><pub-id pub-id-type="pmcid">PMC8606871</pub-id><pub-id pub-id-type="pmid">34806296</pub-id></element-citation></ref><ref id="B146" content-type="misc"><label>146</label><element-citation publication-type="other"><collab>National Institutes of Health (NIH)</collab><article-title>HIV vaccine candidate does not sufficiently protect women against HIV infection</article-title><year>2021</year></element-citation></ref><ref id="B147" content-type="misc"><label>147</label><element-citation publication-type="other"><collab>National Institutes of Health (NIH)</collab><article-title>Experimental HIV vaccine regimen safe but ineffective, study finds</article-title><year>2023</year></element-citation></ref><ref id="B148" content-type="article"><label>148</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Folegatti</surname><given-names>P. M.</given-names></name><name name-style="western"><surname>Jenkin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: standardized template with key considerations for a risk/benefit assessment</article-title><source><italic toggle="yes">Vaccine</italic></source><year>2022</year><volume>40</volume><issue>35</issue><fpage>5248</fpage><lpage>5262</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2022.06.008</pub-id><pub-id pub-id-type="pmid">35715352</pub-id><pub-id pub-id-type="pmcid">PMC9194875</pub-id></element-citation></ref><ref id="B149" content-type="article"><label>149</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ewer</surname><given-names>K. J.</given-names></name><name name-style="western"><surname>Barrett</surname><given-names>J. R.</given-names></name><name name-style="western"><surname>Belij-Rammerstorfer</surname><given-names>S.</given-names></name><etal/></person-group><article-title>T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial</article-title><source><italic toggle="yes">Nature Medicine</italic></source><year>2021</year><volume>27</volume><issue>2</issue><fpage>270</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-01194-5</pub-id><pub-id pub-id-type="pmid">33335323</pub-id></element-citation></ref><ref id="B150" content-type="article"><label>150</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baden</surname><given-names>L. R.</given-names></name><name name-style="western"><surname>Karita</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mutua</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Assessment of the safety and immunogenicity of 2 novel vaccine platforms for HIV-1 prevention: a randomized trial</article-title><source><italic toggle="yes">Annals of Internal Medicine</italic></source><year>2016</year><volume>164</volume><issue>5</issue><fpage>313</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.7326/M15-0880</pub-id><pub-id pub-id-type="other">2-s2.0-84959300660</pub-id><pub-id pub-id-type="pmid">26833336</pub-id><pub-id pub-id-type="pmcid">PMC5034222</pub-id></element-citation></ref><ref id="B151" content-type="article"><label>151</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stephenson</surname><given-names>K. E.</given-names></name><name name-style="western"><surname>Wegmann</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tomaka</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22)</article-title><source><italic toggle="yes">The Lancet HIV</italic></source><year>2020</year><volume>7</volume><issue>6</issue><fpage>e410</fpage><lpage>e421</lpage><pub-id pub-id-type="doi">10.1016/S2352-3018(20)30001-1</pub-id><pub-id pub-id-type="pmid">32078815</pub-id><pub-id pub-id-type="pmcid">PMC7297076</pub-id></element-citation></ref><ref id="B152" content-type="article"><label>152</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baden</surname><given-names>L. R.</given-names></name><name name-style="western"><surname>Stieh</surname><given-names>D. J.</given-names></name><name name-style="western"><surname>Sarnecki</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study</article-title><source><italic toggle="yes">The Lancet HIV</italic></source><year>2020</year><volume>7</volume><issue>10</issue><fpage>e688</fpage><lpage>e698</lpage><pub-id pub-id-type="doi">10.1016/S2352-3018(20)30229-0</pub-id><pub-id pub-id-type="pmid">33010242</pub-id><pub-id pub-id-type="pmcid">PMC7529856</pub-id></element-citation></ref><ref id="B153" content-type="article"><label>153</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhan</surname><given-names>W.</given-names></name><name name-style="western"><surname>Muhuri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tai</surname><given-names>P. W. L.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>G.</given-names></name></person-group><article-title>Vectored immunotherapeutics for infectious diseases: Can rAAVs be the game changers for fighting transmissible pathogens?</article-title><source><italic toggle="yes">Frontiers in Immunology</italic></source><year>2021</year><volume>12</volume><pub-id pub-id-type="doi">10.3389/fimmu.2021.673699</pub-id><pub-id pub-id-type="publisher-id">673699</pub-id><pub-id pub-id-type="pmcid">PMC8144494</pub-id><pub-id pub-id-type="pmid">34046041</pub-id></element-citation></ref><ref id="B154" content-type="article"><label>154</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muhuri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Maeda</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Overcoming innate immune barriers that impede AAV gene therapy vectors</article-title><source><italic toggle="yes">Journal of Clinical Investigation</italic></source><year>2021</year><volume>131</volume><issue>1</issue><pub-id pub-id-type="doi">10.1172/JCI143780</pub-id><pub-id pub-id-type="pmcid">PMC7773343</pub-id><pub-id pub-id-type="pmid">33393506</pub-id></element-citation></ref><ref id="B155" content-type="misc"><label>155</label><element-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Rerks-Ngarm</surname><given-names>S.</given-names></name></person-group><article-title>Clinical study protocol RV144: a phase III trial of Aventis Pasteur Live Recombinant ALVAC-HIV (vCP1521) priming with VaxGen gp120 B/E (AIDSVAX &#174; B/E) boosting in HIV-uninfected Thai adults</article-title><year>2009</year></element-citation></ref><ref id="B156" content-type="article"><label>156</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rerks-Ngarm</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pitisuttithum</surname><given-names>P.</given-names></name><name name-style="western"><surname>Nitayaphan</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand</article-title><source><italic toggle="yes">New England Journal of Medicine</italic></source><year>2009</year><volume>361</volume><issue>23</issue><fpage>2209</fpage><lpage>2220</lpage><pub-id pub-id-type="doi">10.1056/nejmoa0908492</pub-id><pub-id pub-id-type="other">2-s2.0-73349094086</pub-id><pub-id pub-id-type="pmid">19843557</pub-id></element-citation></ref><ref id="B157" content-type="article"><label>157</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>L. P.</given-names></name><name name-style="western"><surname>Fiore-Gartland</surname><given-names>A.</given-names></name><name name-style="western"><surname>Carpp</surname><given-names>L. N.</given-names></name><etal/></person-group><article-title>Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans</article-title><source><italic toggle="yes">PLoS ONE</italic></source><year>2020</year><volume>15</volume><issue>1</issue><pub-id pub-id-type="doi">10.1371/journal.pone.0226803</pub-id><pub-id pub-id-type="publisher-id">e0226803</pub-id><pub-id pub-id-type="pmcid">PMC6992005</pub-id><pub-id pub-id-type="pmid">31999736</pub-id></element-citation></ref><ref id="B158" content-type="article"><label>158</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crowley</surname><given-names>A. R.</given-names></name><name name-style="western"><surname>Ackerman</surname><given-names>M. E.</given-names></name></person-group><article-title>Vaccine boosts: balancing response magnitude and character</article-title><source><italic toggle="yes">The Lancet HIV</italic></source><year>2020</year><volume>7</volume><issue>4</issue><fpage>e217</fpage><lpage>e219</lpage><pub-id pub-id-type="doi">10.1016/S2352-3018(19)30435-7</pub-id><pub-id pub-id-type="pmid">32035517</pub-id></element-citation></ref><ref id="B159" content-type="article"><label>159</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanke</surname><given-names>T.</given-names></name></person-group><article-title>New vector and vaccine platforms: mRNA, DNA, viral vectors</article-title><source><italic toggle="yes">Current Opinion in HIV and AIDS</italic></source><year>2022</year><volume>17</volume><issue>6</issue><fpage>338</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.1097/COH.0000000000000763</pub-id><pub-id pub-id-type="pmid">36178768</pub-id></element-citation></ref><ref id="B160" content-type="article"><label>160</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Timofeeva</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sedykh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nevinsky</surname><given-names>G.</given-names></name></person-group><article-title>Post-immune antibodies in HIV-1 infection in the context of vaccine development: a variety of biological functions and catalytic activities</article-title><source><italic toggle="yes">Vaccines</italic></source><year>2022</year><volume>10</volume><issue>3</issue><pub-id pub-id-type="doi">10.3390/vaccines10030384</pub-id><pub-id pub-id-type="publisher-id">384</pub-id><pub-id pub-id-type="pmcid">PMC8955465</pub-id><pub-id pub-id-type="pmid">35335016</pub-id></element-citation></ref><ref id="B161" content-type="article"><label>161</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khalid</surname><given-names>K.</given-names></name><name name-style="western"><surname>Padda</surname><given-names>J.</given-names></name><name name-style="western"><surname>Khedr</surname><given-names>A.</given-names></name><etal/></person-group><article-title>HIV and messenger RNA (mRNA) vaccine</article-title><source><italic toggle="yes">Cureus</italic></source><year>2021</year><volume>13</volume><issue>7</issue><pub-id pub-id-type="doi">10.7759/cureus.16197</pub-id><pub-id pub-id-type="publisher-id">e16197</pub-id><pub-id pub-id-type="pmcid">PMC8341208</pub-id><pub-id pub-id-type="pmid">34367800</pub-id></element-citation></ref><ref id="B162" content-type="article"><label>162</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tian</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name></person-group><article-title>Development of therapeutic vaccines for the treatment of diseases</article-title><source><italic toggle="yes">Molecular Biomedicine</italic></source><year>2022</year><volume>3</volume><pub-id pub-id-type="doi">10.1186/s43556-022-00098-9</pub-id><pub-id pub-id-type="publisher-id">40</pub-id><pub-id pub-id-type="pmcid">PMC9729511</pub-id><pub-id pub-id-type="pmid">36477638</pub-id></element-citation></ref><ref id="B163" content-type="article"><label>163</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Julg</surname><given-names>B.</given-names></name></person-group><article-title>Therapeutic vaccines for the treatment of HIV</article-title><source><italic toggle="yes">Translational Research</italic></source><year>2020</year><volume>223</volume><fpage>61</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1016/j.trsl.2020.04.008</pub-id><pub-id pub-id-type="pmid">32438074</pub-id><pub-id pub-id-type="pmcid">PMC8188575</pub-id></element-citation></ref><ref id="B164" content-type="article"><label>164</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Espinar-Buitrago</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mu&#241;oz-Fern&#225;ndez</surname><given-names>M. A.</given-names></name></person-group><article-title>New approaches to dendritic cell-based therapeutic vaccines against HIV-1 infection</article-title><source><italic toggle="yes">Frontiers in Immunology</italic></source><year>2022</year><volume>12</volume><pub-id pub-id-type="doi">10.3389/fimmu.2021.719664</pub-id><pub-id pub-id-type="publisher-id">719664</pub-id><pub-id pub-id-type="pmcid">PMC8763680</pub-id><pub-id pub-id-type="pmid">35058917</pub-id></element-citation></ref><ref id="B165" content-type="article"><label>165</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moretti</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cafaro</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tripiciano</surname><given-names>A.</given-names></name><etal/></person-group><article-title>HIV therapeutic vaccines aimed at intensifying combination antiretroviral therapy</article-title><source><italic toggle="yes">Expert Review of Vaccines</italic></source><year>2020</year><volume>19</volume><issue>1</issue><fpage>1243</fpage><lpage>1253</lpage><pub-id pub-id-type="doi">10.1080/14760584.2020.1712199</pub-id><pub-id pub-id-type="pmid">31957513</pub-id></element-citation></ref><ref id="B166" content-type="article"><label>166</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buchbinder</surname><given-names>S. P.</given-names></name><name name-style="western"><surname>Mehrotra</surname><given-names>D. V.</given-names></name><name name-style="western"><surname>Duerr</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the step study): a double-blind, randomised, placebo-controlled, test-of-concept trial</article-title><source><italic toggle="yes">The Lancet</italic></source><year>2008</year><volume>372</volume><issue>9653</issue><fpage>1881</fpage><lpage>1893</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(08)61591-3</pub-id><pub-id pub-id-type="other">2-s2.0-56649105122</pub-id><pub-id pub-id-type="pmcid">PMC2721012</pub-id><pub-id pub-id-type="pmid">19012954</pub-id></element-citation></ref><ref id="B167" content-type="incollection"><label>167</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Mothe</surname><given-names>B.</given-names></name><name name-style="western"><surname>Brander</surname><given-names>C.</given-names></name></person-group><person-group person-group-type="editor"><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lewin</surname><given-names>S.</given-names></name></person-group><article-title>HIV T-cell vaccines</article-title><source><italic toggle="yes">HIV Vaccines and Cure</italic></source><year>2018</year><volume>1075</volume><publisher-loc>New York LLC</publisher-loc><publisher-name>Springer</publisher-name><fpage>31</fpage><lpage>51</lpage><series>Advances in Experimental Medicine and Biology</series><pub-id pub-id-type="doi">10.1007/978-981-13-0484-2_2</pub-id><pub-id pub-id-type="other">2-s2.0-85051123921</pub-id><pub-id pub-id-type="pmid">30030788</pub-id></element-citation></ref><ref id="B168" content-type="article"><label>168</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martinsen</surname><given-names>J. T.</given-names></name><name name-style="western"><surname>Gunst</surname><given-names>J. D.</given-names></name><name name-style="western"><surname>H&#248;jen</surname><given-names>J. F.</given-names></name><name name-style="western"><surname>Tolstrup</surname><given-names>M.</given-names></name><name name-style="western"><surname>S&#248;gaard</surname><given-names>O. S.</given-names></name></person-group><article-title>The use of toll-like receptor agonists in HIV-1 cure strategies</article-title><source><italic toggle="yes">Frontiers in Immunology</italic></source><year>2020</year><volume>11</volume><pub-id pub-id-type="doi">10.3389/fimmu.2020.01112</pub-id><pub-id pub-id-type="publisher-id">1112</pub-id><pub-id pub-id-type="pmcid">PMC7300204</pub-id><pub-id pub-id-type="pmid">32595636</pub-id></element-citation></ref><ref id="B169" content-type="article"><label>169</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rozman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zidovec-Lepej</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jambrosic</surname><given-names>K.</given-names></name><name name-style="western"><surname>Babi&#263;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Drmi&#263; Hofman</surname><given-names>I.</given-names></name></person-group><article-title>Role of TLRs in HIV-1 infection and potential of TLR agonists in HIV-1 vaccine development and treatment strategies</article-title><source><italic toggle="yes">Pathogens</italic></source><year>2023</year><volume>12</volume><issue>1</issue><pub-id pub-id-type="doi">10.3390/pathogens12010092</pub-id><pub-id pub-id-type="publisher-id">92</pub-id><pub-id pub-id-type="pmcid">PMC9866513</pub-id><pub-id pub-id-type="pmid">36678440</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="fig1" orientation="portrait"><label>Figure 1</label><caption><p>Schematic representation of functional Env and the generation of anti-idiotype antibodies. HIV Env is a trimer of heterodimers consisting of the surface glycoprotein gp120 and the transmembrane glycoprotein gp41 noncovalently associated. Located on gp120, there are major Abs binding sites reported in (a). The CD4bs is a target of the most potent bNAbs (b, c). Anti-CD4bs Abs (blue) can be used as immunogen for animal immunization (d) eliciting the production of anti-Id Abs (yellow) against recombinant and cellular human CD4 due to their capability to mimic CD4bs of the gp120 (e). Created with <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://BioRender.com" ext-link-type="uri">BioRender.com</ext-link>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="JIR2024-2147912.001.jpg"/></fig><fig position="float" id="fig2" orientation="portrait"><label>Figure 2</label><caption><p>Schematic representation of different workflow strategies to produce new HIV-1 immunogens based on bNAbs strucure. Various antibody-based vaccination strategies have been used to develop new immunogens against HIV-1 infection. Although the techniques are numbered sequentially, there is no specific order in which they should be followed when creating novel immunogens. (1) B cell-lineage vaccine design. It involves the isolation of broad neutralizing antibodies (bNAbs) producing B cells and computationally reconstructing the whole B cell clonal lineages to replicate the molecular phylogenesis of the isolate bNAb, which will include all of its ancestral intermediates to the UCA. The ancestral intermediates and UCA act as molecular guides in immunogen development for different vaccine techniques such as germline-targeting, mutation-guided, and structure-guided immunogen design. (2) Germline targeting. Unfortunately, bNAbs UCAs cannot bind to most Env proteins, so germline targeting selects the best Env immunogen (by screening the Env variants library) that binds UCA and then uses it to construct a variety of high-affinity bNAbs precursors. The knowledge of the epitope structure can be improved using mutation-guided and structure-based immunogen design. (3) Mutation-guided immunogen design. It reflects the discovery of improbable broad neutralize mutations in ancestral intermediate bNAbs, which will be tested in an in vitro broad neutralization assay. Finally, mutated bNAbs will help to develop new immunogens. (4) Structure-based immunogen design. It consists of the atomic level characterization of the bNAbs-Env complex. It enables bioinformatic modeling of the Env immunogen around the Ab and its precursors to improve binding by introducing epitope alterations that result in the creation of the immunogen. Created with <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://BioRender.com" ext-link-type="uri">BioRender.com</ext-link>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="JIR2024-2147912.002.jpg"/></fig><table-wrap position="float" id="tab1" orientation="portrait"><label>Table 1</label><caption><p>HIV-1 main genes and protein functions encoded.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Class</th><th align="center" rowspan="1" colspan="1">Gene</th><th align="center" rowspan="1" colspan="1">Polyprotein</th><th align="center" rowspan="1" colspan="1">Protein(s)</th><th align="left" rowspan="1" colspan="1">Function(s)</th><th align="center" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="left" rowspan="3" colspan="1">Viral structural proteins</td><td align="center" rowspan="1" colspan="1">
<italic toggle="yes">gag</italic>
</td><td align="center" rowspan="1" colspan="1">Gag</td><td align="center" rowspan="1" colspan="1">Matrix (MA, p17)<break/>Capsid (CA, p24)<break/>Nucleocapsid (NC, p7)</td><td align="left" rowspan="1" colspan="1">Encodes a polyprotein that is processed to form the structural proteins placed inside the envelope</td><td align="center" rowspan="1" colspan="1">[<xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B24" ref-type="bibr">24</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">
<italic toggle="yes">pol</italic>
</td><td align="center" rowspan="1" colspan="1">Pol</td><td align="center" rowspan="1" colspan="1">Protease (PR, p12)<break/><break/>Reverse transcriptase (RT, p66) and RNaseH (p51)<break/><break/>Integrase (IN, p32)</td><td align="left" rowspan="1" colspan="1">Proteolytic cut of Gag/Pol proteins.<break/>When in the cytoplasm, RT transcribes viral RNA into a complementary copy of DNA, resulting in the formation of dsDNA. RNaseH degrades viral RNA.<break/>In the nucleus, the integration of HIV dsDNA occurs into the host cellular genome by IN (formation of the provirus)</td><td align="center" rowspan="1" colspan="1">[<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B25" ref-type="bibr">25</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">
<italic toggle="yes">env</italic>
</td><td align="center" rowspan="1" colspan="1">PrGp (gp160)</td><td align="center" rowspan="1" colspan="1">Surface protein (SU, gp120)<break/>Transmembrane protein (TM, gp41)</td><td align="left" rowspan="1" colspan="1">It fuses the viral and cell membranes after binding to the cellular receptor; gp160 undergoes a series of conformational changes, and it is cleaved in gp120 and gp41</td><td align="center" rowspan="1" colspan="1">[<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B26" ref-type="bibr">26</xref>]</td></tr><tr><td colspan="6" align="center" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="2" colspan="1">Essential regulatory elements</td><td align="center" rowspan="1" colspan="1">
<italic toggle="yes">tat</italic>
</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">Tat</td><td align="left" rowspan="1" colspan="1">Transactivator; activates transcription of viral DNA and cellular genes</td><td align="center" rowspan="1" colspan="1">[<xref rid="B27" ref-type="bibr">27</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">
<italic toggle="yes">rev</italic>
</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">Rev</td><td align="left" rowspan="1" colspan="1">Gene transcription regulator of virion proteins. Rev facilitates viral unspliced mRNAs transport from the nucleus to the cytoplasm for their translation</td><td align="center" rowspan="1" colspan="1">[<xref rid="B25" ref-type="bibr">25</xref>]</td></tr><tr><td colspan="6" align="center" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="4" colspan="1">Accessory regulatory proteins</td><td align="center" rowspan="1" colspan="1">
<italic toggle="yes">nef</italic>
</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">Negative regulating factor</td><td align="left" rowspan="1" colspan="1">Nef is a protein that affects HIV replication, viral particle infectivity, CD4 downregulation and apoptosis</td><td align="center" rowspan="1" colspan="1">[<xref rid="B24" ref-type="bibr">24</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">
<italic toggle="yes">vif</italic>
</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">Viral infectivity factor</td><td align="left" rowspan="1" colspan="1">Vif regulates virus infectivity through the degradation of human APOBEC3G (cellular cytidine deaminase) protein, which provide innate immunity against various pathogens</td><td align="center" rowspan="1" colspan="1">[<xref rid="B28" ref-type="bibr">28</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">
<italic toggle="yes">vpr</italic>
</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">Viral protein R</td><td align="left" rowspan="1" colspan="1">Vpr controls the import of the HIV-1 dsDNA preintegration complex into the nucleus, the activation and apoptosis of infected cells, virus transcription, and cell cycle arrest</td><td align="center" rowspan="1" colspan="1">[<xref rid="B29" ref-type="bibr">29</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">
<italic toggle="yes">vpu</italic>
</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">Viral protein U</td><td align="left" rowspan="1" colspan="1">Vpu increases the release of viral particles from human cells and contributes to the overall downregulation of CD4s expression throughout HIV-1 infection by inducing their degradation</td><td align="center" rowspan="1" colspan="1">[<xref rid="B30" ref-type="bibr">30</xref>]</td></tr></tbody></table></table-wrap><table-wrap position="float" id="tab2" orientation="portrait"><label>Table 2</label><caption><p>Summary of the vectors mentioned in the &#8220;Alternative Vaccination Strategies Based on Vectors&#8221; section.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Molecule</th><th align="center" rowspan="1" colspan="1">Vector type</th><th align="center" rowspan="1" colspan="1">Study ID</th><th align="center" rowspan="1" colspan="1">Clinical trials identifier</th><th align="center" rowspan="1" colspan="1">Year started</th><th align="left" rowspan="1" colspan="1">Immunogen/description</th><th align="center" rowspan="1" colspan="1">Country</th><th align="center" rowspan="1" colspan="1">Population enrolled</th><th align="center" colspan="2" rowspan="1">Note</th><th align="center" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="left" rowspan="5" colspan="1">DNA viruses</td><td align="center" rowspan="4" colspan="1">Adenovirus</td><td align="center" rowspan="1" colspan="1">HVNT 502</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">2004</td><td align="left" rowspan="1" colspan="1">Human adenovirus-based vector type 5/HIV-1 proteins clade B (Gag, Pol, Nef)<break/>MRKAd5 HIV-1gag/pol/nef trivalent vaccine</td><td align="center" rowspan="1" colspan="1">US, The Caribbean, Australia</td><td align="center" colspan="2" rowspan="1">Homosexual men and high-risk heterosexual men and women</td><td align="center" rowspan="1" colspan="1">Clinical trial stopped</td><td align="center" rowspan="1" colspan="1">[<xref rid="B125" ref-type="bibr">125</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">HVNT 503</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00413725">NCT00413725</ext-link></td><td align="center" rowspan="1" colspan="1">2007</td><td align="left" rowspan="1" colspan="1">Human adenovirus-based vector type 5/HIV-1 proteins clade B (Gag, Pol, Nef)<break/>MRKAd5 HIV-1gag/pol/nef trivalent vaccine</td><td align="center" rowspan="1" colspan="1">South Africa</td><td align="center" colspan="2" rowspan="1">Healthy adults of both sexes</td><td align="center" rowspan="1" colspan="1">Clinical trial stopped</td><td align="center" rowspan="1" colspan="1">[<xref rid="B126" ref-type="bibr">126</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">IPCAVD001</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00618605">NCT00618605</ext-link></td><td align="center" rowspan="1" colspan="1">2008</td><td align="left" rowspan="1" colspan="1">Assess safety and immunogenicity of the recombinant adenovirus serotype 26 (Ad26.ENVA.01) which contains a HIV-1 Clade A <italic toggle="yes">Env</italic> gene encoding a modified envelope gp140 protein</td><td align="center" rowspan="1" colspan="1">US</td><td align="center" colspan="2" rowspan="1">Healthy adults of both sexes</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">[<xref rid="B127" ref-type="bibr">127</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">HVNT 505</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00865566">NCT00865566</ext-link></td><td align="center" rowspan="1" colspan="1">2009</td><td align="left" rowspan="1" colspan="1">Recombinant adenoviral serotype 5 (rAd5) vector vaccine encoding HIV-1 clade B Gag/Pol and<break/>HIV-1 clade A, B, C Nef/Env</td><td align="center" rowspan="1" colspan="1">US</td><td align="center" colspan="2" rowspan="1">Healthy, circumcised men, and male-to-female transgender persons<break/>who have sex with men</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">[<xref rid="B128" ref-type="bibr">128</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">Adeno-associated virus</td><td align="center" rowspan="1" colspan="1">IAVI A003</td><td align="center" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01937455" ext-link-type="uri">NCT01937455</ext-link>
</td><td align="center" rowspan="1" colspan="1">2014</td><td align="left" rowspan="1" colspan="1">Recombinant AAV vector coding for PG9 antibody which is a human monoclonal IgG1 antibody that reacts with the V1V2 loop of the HIV-1 envelope gp120 protein and was derived from a patient with clade A HIV infection<break/>rAAV1-PG9DP</td><td align="center" rowspan="1" colspan="1">UK</td><td align="center" colspan="2" rowspan="1">Healthy adult males</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">[<xref rid="B129" ref-type="bibr">129</xref>]</td></tr><tr><td colspan="11" align="center" rowspan="1">
<hr/>
</td></tr><tr><td rowspan="7" align="left" colspan="1">DNA viruses</td><td rowspan="7" align="center" colspan="1">Pox virus</td><td align="center" rowspan="1" colspan="1">RV144</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00223080">NCT00223080</ext-link></td><td align="center" rowspan="1" colspan="1">2003</td><td align="left" rowspan="1" colspan="1">Prime: recombinant canarypox vector vaccine (ALVAC-HIV (vCP1521)) expressing subtype E HIV-1 gp120 (strain 92TH023) linked to the transmembrane anchoring portion of gp41 (strain LAI), and HIV-1 gag and protease (LAI strain) Boost: AIDSVAX&#174; B/E, a highly purified mixture of gp120 proteins</td><td align="center" rowspan="1" colspan="1">Thailand</td><td colspan="2" align="center" rowspan="1">Healthy adults of both sexes</td><td align="center" rowspan="1" colspan="1">P<sub>AE/B</sub>/alum</td><td align="center" rowspan="1" colspan="1">[<xref rid="B130" ref-type="bibr">130</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">RV305</td><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01435135">NCT01435135</ext-link></td><td align="center" rowspan="1" colspan="1">2012</td><td align="left" rowspan="1" colspan="1">6&#8211;8 years late boost since RV144 vaccination: ALVAC-HIV&#8201;+&#8201;AIDSVAX&#174; B/E, AIDSVAX&#174; B/E, and ALVAC-HIV</td><td align="center" rowspan="1" colspan="1">Thailand</td><td colspan="2" align="center" rowspan="1">Participants in RV144clinical trial</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">[<xref rid="B131" ref-type="bibr">131</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">HVNT 096</td><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01799954">NCT01799954</ext-link></td><td align="center" rowspan="1" colspan="1">2012</td><td align="left" rowspan="1" colspan="1">Experimental HIV vaccine regimens using different vaccine priming combination, and boosting with the vaccines NYVAC and AIDSVAX&#174; B/E</td><td align="center" rowspan="1" colspan="1">Switzerland</td><td colspan="2" align="center" rowspan="1">Healthy adults of both sexes</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">[<xref rid="B132" ref-type="bibr">132</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">HVNT 097</td><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02109354">NCT02109354</ext-link></td><td align="center" rowspan="1" colspan="1">2013</td><td align="left" rowspan="1" colspan="1">Prime: recombinant canarypox vector vaccine (ALVAC-HIV (vCP1521))Boost: AIDSVAX&#174; B/E</td><td align="center" rowspan="1" colspan="1">South Africa</td><td colspan="2" align="center" rowspan="1">Healthy adults of both sexes</td><td align="center" rowspan="1" colspan="1">P<sub>AE/B</sub>/alum</td><td align="center" rowspan="1" colspan="1">[<xref rid="B133" ref-type="bibr">133</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">RV306</td><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01931358">NCT01931358</ext-link></td><td align="center" rowspan="1" colspan="1">2013</td><td align="left" rowspan="1" colspan="1">12, 15, or 18 months late boost since RV144 Vaccination: ALVAC-HIV&#8201;+&#8201;AIDSVAX&#174; B/E, AIDSVAX&#174; B/E, and ALVAC-HIV</td><td align="center" rowspan="1" colspan="1">Thailand</td><td colspan="2" align="center" rowspan="1">Healthy adults of both sexes</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">[<xref rid="B134" ref-type="bibr">134</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">HVNT 100</td><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02404311">NCT02404311</ext-link></td><td align="center" rowspan="1" colspan="1">2015</td><td align="left" rowspan="1" colspan="1">Prime: ALVAC-HIV vector (vCP2438)&#8212;expressing HIV-1 Env gp120 (subtype C), the transmembrane region of Env gp41, gag, and protease (all subtype B). Boost: Bivalent subtype C gp120/MF59&#174;</td><td align="center" rowspan="1" colspan="1">South Africa</td><td colspan="2" align="center" rowspan="1">Healthy adults of both sexes</td><td align="center" rowspan="1" colspan="1">P<sub>C</sub>/MF59</td><td align="center" rowspan="1" colspan="1">[<xref rid="B135" ref-type="bibr">135</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">HVNT 702</td><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02968849">NCT02968849</ext-link></td><td align="center" rowspan="1" colspan="1">2016</td><td align="left" rowspan="1" colspan="1">ALVAC-HIV (vCP2438) expressing the HIV-1 envelope glycoprotein of the subtype C, along with the gp41 transmembrane sequence, gag, and protease from the subtype B LAI strain&#8201;+&#8201;Bivalent subtype C gp120/MF59</td><td align="center" rowspan="1" colspan="1">South Africa</td><td colspan="2" align="center" rowspan="1">Healthy adults of both sexes</td><td align="center" rowspan="1" colspan="1">Clinical trial stopped</td><td align="center" rowspan="1" colspan="1">[<xref rid="B136" ref-type="bibr">136</xref>]</td></tr><tr><td colspan="11" align="center" rowspan="1">
<hr/>
</td></tr><tr><td rowspan="3" align="left" colspan="1">RNA viruses</td><td rowspan="3" align="center" colspan="1">mRNA</td><td align="center" rowspan="1" colspan="1">iHIVARNA</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02413645">NCT02413645</ext-link></td><td align="center" rowspan="1" colspan="1">2015</td><td align="left" rowspan="1" colspan="1">Naked mRNA containing dendritic cell activation signals iHIVARNA-01 (TriMix) and encoding a novel HIV immunogen sequence (HIVACAT T-cell immunogen) (HTI))</td><td align="center" rowspan="1" colspan="1">Spain</td><td colspan="2" align="center" rowspan="1">HIV-1 infected adults of both sexes</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">[<xref rid="B137" ref-type="bibr">137</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">iHIVARNA phase II</td><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02888756">NCT02888756</ext-link></td><td align="center" rowspan="1" colspan="1">2017</td><td align="left" rowspan="1" colspan="1">HIVACAT-TriMix aloneTriMix alone</td><td align="center" rowspan="1" colspan="1">Belgium, Netherlands, Spain</td><td colspan="2" align="center" rowspan="1">HIV-1 infected adults of both sexes</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">[<xref rid="B138" ref-type="bibr">138</xref>]</td></tr><tr><td align="center" rowspan="1" colspan="1">HVNT 302</td><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05217641">NCT05217641</ext-link></td><td align="center" rowspan="1" colspan="1">2022</td><td align="left" rowspan="1" colspan="1">Evaluation of the safety and immunogenicity of BG505 MD39.3, BG505 MD39.3 gp151, and BG505 MD39.3 gp151 CD4KO HIV trimer mRNA. These trimers are based on the BG505 MD39 native-like trimer reported in PMID: 27617678</td><td align="center" rowspan="1" colspan="1">US</td><td colspan="2" align="center" rowspan="1">Healthy adults of both sexes</td><td align="center" rowspan="1" colspan="1">Clinical trial not completed</td><td align="center" rowspan="1" colspan="1">&#8212;</td></tr></tbody></table></table-wrap><table-wrap position="float" id="tab3" orientation="portrait"><label>Table 3</label><caption><p>HIV-1 clinical trial that used Mosaic vaccine design.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Study ID</th><th align="center" rowspan="1" colspan="1">Clinical trials identifier</th><th align="center" rowspan="1" colspan="1">Year started</th><th align="left" rowspan="1" colspan="1">Immunogen/description</th><th align="center" rowspan="1" colspan="1">Country</th><th align="center" rowspan="1" colspan="1">Population enrolled</th><th align="center" rowspan="1" colspan="1">Note</th><th align="center" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">IAVI B003</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01215149">NCT01215149</ext-link></td><td align="center" rowspan="1" colspan="1">2010</td><td align="left" rowspan="1" colspan="1">Adenovirus serotype 26 with an HIV-1 envelope A insert (Ad26.EnvA)<break/>Adenovirus serotype 35 with an HIV-1 envelope A insert (Ad35.Env)</td><td align="center" rowspan="1" colspan="1">US, Kenya<break/>Rwanda, South Africa</td><td align="center" rowspan="1" colspan="1">Healthy adults<break/>of both sexes</td><td align="center" rowspan="1" colspan="1">Homologous and heterologous regimens</td><td align="center" rowspan="1" colspan="1">[<xref rid="B150" ref-type="bibr">150</xref>]</td></tr><tr><td colspan="8" align="center" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">MENSCH</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02218125">NCT02218125</ext-link></td><td align="center" rowspan="1" colspan="1">2014</td><td align="left" rowspan="1" colspan="1">MVA-vectored HIV-1 bivalent mosaic immunogen vaccine (MVA.mos1 and MVA.mos2; MVA Mosaic) which delivered two different but complementary HIV-1 <italic toggle="yes">gag/pol/env</italic> inserts</td><td align="center" rowspan="1" colspan="1">US, Kenya<break/>Rwanda, South Africa</td><td align="center" rowspan="1" colspan="1">Healthy adults of both sexes and<break/>those who had received two or three doses of <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00618605">NCT00618605</ext-link></td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">[<xref rid="B127" ref-type="bibr">127</xref>]</td></tr><tr><td colspan="8" align="center" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">APPROACH</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02315703">NCT02315703</ext-link></td><td align="center" rowspan="1" colspan="1">2014</td><td align="left" rowspan="1" colspan="1">Prime: Ad26.Mos1.Env, Ad26.Mos1.Gag-Pol, and Ad26.Mos2.Gag-Pol<break/>Boost: Ad26.Mos.HIV or MVA-mosaic with or without gp140 protein</td><td align="center" rowspan="1" colspan="1">US, Rwanda,<break/>South Africa, Thailand, Uganda</td><td align="center" rowspan="1" colspan="1">Healthy adults<break/>of both sexes</td><td align="center" rowspan="1" colspan="1">Aluminum phosphate adjuvanted with clade C Env gp140 protein</td><td align="center" rowspan="1" colspan="1">[<xref rid="B144" ref-type="bibr">144</xref>]</td></tr><tr><td colspan="8" align="center" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="CR108068">CR108068</ext-link></td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02685020">NCT02685020</ext-link></td><td align="center" rowspan="1" colspan="1">2016</td><td align="left" rowspan="1" colspan="1">Ad26.Mos.HIV mosaic Env, Gag, and Pol antigens<break/>Clade C gp140</td><td align="center" rowspan="1" colspan="1">US</td><td align="center" rowspan="1" colspan="1">Healthy adults<break/>of both sexes</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">[<xref rid="B151" ref-type="bibr">151</xref>]</td></tr><tr><td colspan="8" align="center" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">TRAVERSE</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02788045">NCT02788045</ext-link></td><td align="center" rowspan="1" colspan="1">2016</td><td align="left" rowspan="1" colspan="1">Prime: trivalent Ad26.Mos.HIV or tetravalent Ad26.Mos4.HIV<break/>Boost: trivalent Ad26.Mos.HIV and Clade C gp140 plus adjuvant or Ad26.Mos4.HIV and Clade C gp140 plus adjuvant</td><td align="center" rowspan="1" colspan="1">US, Rwanda</td><td align="center" rowspan="1" colspan="1">Healthy adults<break/>of both sexes</td><td align="center" rowspan="1" colspan="1">&#8212;</td><td align="center" rowspan="1" colspan="1">[<xref rid="B152" ref-type="bibr">152</xref>]</td></tr><tr><td colspan="8" align="center" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">ASCENT</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02935686">NCT02935686</ext-link></td><td align="center" rowspan="1" colspan="1">2017</td><td align="left" rowspan="1" colspan="1">Prime: tetravalent Ad26.Mos4.HIV<break/>Boost: tetravalent Ad26.Mos4.HIV and Clade C gp140 plus adjuvant or a combination of Mosaic gp140 and Clade C gp140 plus adjuvant or HIV Bivalent Vaccine</td><td align="center" rowspan="1" colspan="1">US, Kenya, Rwanda</td><td align="center" rowspan="1" colspan="1">Healthy adults<break/>of both sexes</td><td align="center" rowspan="1" colspan="1">Clinical trial not completed</td><td align="center" rowspan="1" colspan="1">&#8212;</td></tr><tr><td colspan="8" align="center" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">IMBOKODO</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03060629">NCT03060629</ext-link></td><td align="center" rowspan="1" colspan="1">2017</td><td align="left" rowspan="1" colspan="1">Prime: tetravalent Ad26.Mos4.HIV<break/>Boost: Clade C gp140 with aluminum phosphate adjuvant</td><td align="center" rowspan="1" colspan="1">Malawi, Mozambique, South Africa, Zambia, Zimbabwe</td><td align="center" rowspan="1" colspan="1">Healthy, sexually active with male partners, at risk for HIV-1, adult females</td><td align="center" rowspan="1" colspan="1">The vaccine did not prevent HIV infection in high-risk women</td><td align="center" rowspan="1" colspan="1">[<xref rid="B146" ref-type="bibr">146</xref>]</td></tr><tr><td colspan="8" align="center" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">IGHID 11810</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03844386">NCT03844386</ext-link></td><td align="center" rowspan="1" colspan="1">2019</td><td align="left" rowspan="1" colspan="1">Pilot study to evaluate the safety and immunogenicity of: MVA.tHIVconsv3 and MVA.tHIVconsv4, administered alone or in combination. Expression immunogens derived from conserved yet immunogenic regions of HIV-1</td><td align="center" rowspan="1" colspan="1">US</td><td align="center" rowspan="1" colspan="1">HIV-1 infected adults<break/>of both sexes under ART</td><td align="center" rowspan="1" colspan="1">Clinical trial completed, but no publications available</td><td align="center" rowspan="1" colspan="1">&#8212;</td></tr><tr><td colspan="8" align="center" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">MOSAICO</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03964415">NCT03964415</ext-link></td><td align="center" rowspan="1" colspan="1">2020</td><td align="left" rowspan="1" colspan="1">Prime: Ad26.Mos4.HIV is a tetravalent vaccine composed of Ad26.Mos1.Gag-Pol, Ad26.Mos2.Gag-Pol, Ad26.Mos1.Env, and Ad26.Mos2S.Env Clade C<break/>Boost: Clade C and Mosaic gp140 HIV bivalent vaccine which contains: Clade C gp140, HIV-1 Env gp140 of Clade C, Mosaic gp140, HIV-1 Env gp140, and aluminum phosphate adjuvant</td><td align="center" rowspan="1" colspan="1">Uganda</td><td align="center" rowspan="1" colspan="1">Homosexual and bisexual men and trans women</td><td align="center" rowspan="1" colspan="1">Clinical trial stopped. According to the data, those who received the vaccine continued to contract HIV at a rate that was comparable to that of the other group</td><td align="center" rowspan="1" colspan="1">&#8212;</td></tr><tr><td colspan="8" align="center" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">HIV-CORE 0052</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04586673">NCT04586673</ext-link></td><td align="center" rowspan="1" colspan="1">2021</td><td align="left" rowspan="1" colspan="1">Safety profile evaluation of: ChAdOx1.tHIVconv1, MVA.tHIVconsv3, and MVA.tHIVconsv4</td><td align="center" rowspan="1" colspan="1">UK</td><td align="center" rowspan="1" colspan="1">Healthy adults<break/>of both sexes</td><td align="center" rowspan="1" colspan="1">Clinical trial completed, but no publications available</td><td align="center" rowspan="1" colspan="1">&#8212;</td></tr><tr><td colspan="8" align="center" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">HIV-CORE 006</td><td align="center" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04553016">NCT04553016</ext-link></td><td align="center" rowspan="1" colspan="1">2021</td><td align="left" rowspan="1" colspan="1">Prime: ChAdOx1.tHIVconv1 <break/>Boost: MVA.tHIVconsv3 and MVA.tHIVconsv4</td><td align="center" rowspan="1" colspan="1">Kenya, Uganda,<break/>Zambia</td><td align="center" rowspan="1" colspan="1">Healthy adults of both sexes</td><td align="center" rowspan="1" colspan="1">Clinical trial completed, but no publications available</td><td align="center" rowspan="1" colspan="1">&#8212;</td></tr></tbody></table></table-wrap></floats-group></article></pmc-articleset>